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Abstract 
 
Peptide-based probes are developed into imaging agents to target two different 
receptors: receptor for HA mediated motility (RHAMM) and glucagon-like peptide 1 receptor 
(GLP-1R). 
 In the first project, peptides are derived from tubulin and mimic HA (hyaluronan), the 
natural ligand of RHAMM. In order to develop the lead candidate peptides into imaging 
agents, a DOTA chelator which can coordinate a radiometal was coupled onto the lead 
peptides. Gallium labelling studies were performed and the labelled probes were used in in 
vivo mouse studies. Various analogues of two of the candidate peptides were also 
synthesized using bioisosteric, unnatural as well as natural amino acid replacements. They 
were incubated with RHAMM-coated magnetic/fluorescent beads and screened using a 
plate reader. This project resulted in the conclusion that the peptides containing only natural 
amino acids are not adequate imaging agents, but led to the discovery of novel peptides that 
have more potential as probes targeting RHAMM in vivo. 
In the second project, truncated GLP-1 analogues were synthesized and 
characterized. The unnatural amino acids, BIP 1 and BIP 2 were first synthesized before 
being incorporated into the peptides. The potential of the peptides were analyzed by binding 
assays which determine the IC50 and EC50. The two DOTA chelated peptides were 
coordinated with 68Ga and in vitro cell studies were performed. Ultimately, this research 
found an allosteric agonist for the GLP-1R which may have the potential to be a PET 
imaging probe to monitor type 2 diabetes. 
Keywords 
Molecular imaging, radiochemistry, gallium-68, hyaluronan, receptor for hyaluronan 
mediated motility (RHAMM), tubulin, carboxy terminal tail, bioisostere, breast cancer, 
diabetes, GLP-1R 
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Chapter 1: Introduction 
1.1 Molecular Imaging                                                                                                                                                                                  
Imaging techniques have helped shape our understanding of various diseases. 
Recently, it has become possible to visualize specific molecules and targets.1 This 
research discipline is called molecular imaging and is defined as a method to non-
invasively visualize, characterize and quantify biological processes at the molecular and 
cellular levels.2 Molecular imaging has been shown to play a significant role in modern 
medicine due to its potential application in diagnostics and therapeutics. In order for the 
non-invasive in vivo visualization of biological processes to be feasible, it requires the 
development of an appropriately designed imaging probe.  
 
1.2    Imaging Probes 
 The non-invasive visualization of biological processes in vivo requires the 
discovery and development of novel imaging agents. There are two main classes of 
probes: non-specific and targeted. Non-specific probes, instead of interacting with 
specific receptors, emphasize dissimilarities between tissues relating to permeability and 
perfusion levels and have compartmental distributions. The design of non-specific 
agents relies on general chemical properties such as size, charge and hydrophilicity to 
determine the distribution in the body.3 These probes are typically used to image 
physiological processes such as changes in blood volume, perfusion and blood flow in 
angiogenesis.4 Often the compartmental distribution changes over time, so fast imaging 
might be required. There are numerous non-targeted probes that currently exist in the 
clinic, such as PET (13N-ammonia)5 and SPECT (99mTc-sestamibi)6 probes used for 
perfusion imaging. Also, gold nanoparticles that target tumours via the enhanced 
permeability and retention effect are being utilized in pre-clinical studies.7  
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Figure 1.1 Structure of 99mTc-sestamibi6 
 
In contrast to non-specific probes, targeted probes, the strictest category of 
molecular imaging, are designed to target a specific site within the body such as a breast 
cancer tumour. The probe typically consists of two main components: the targeting 
entity, which is a chemical that can be a small molecule, peptide or other biomolecule 
able to recognize and bind with high affinity to a particular biological receptor, and the 
label which provides the signal for detection (Figure 1.2).                                                                                                                                                                                                                                                   
                     
Figure 1.2 Components of a molecular imaging probe containing the targeting entity, the 
linker and a label 
 
 Depending on the modality of choice, the label can be organic fluorophores or 
inorganic quantum dots for optical imaging8 or radioisotopes for nuclear imaging. 
Sometimes, there may be a linker present to add distance between the label and the 
targeting entity to allow for proper receptor-ligand binding. Targeted probes are 
detectable at all times, regardless of any interaction with the biological target, which 
 3 
 
leads to higher background noise levels.9 However, considering that only the probes 
bound to the biological targets stay in the system, higher signal to noise ratios can be 
obtained if waiting periods are permitted prior to imaging. There are a number of 
necessary prerequisites for a targeting entity to be useful in nuclear medicine. The 
targeting entity must preferentially go to a desired part of the body and be able to move 
quickly to the area of interest, because of the time constraints imposed by using 
radionuclides. Additionally, the targeting moiety should not produce an immune 
response within the patient as well as being able to be cleared from the body after the 
imaging has been completed in order to minimize exposure to radiation.9 As a result of 
the conditions necessary for a useful targeting entity, the development of molecular 
imaging agents relies heavily on the discovery and development of new targeting 
entities. 
 
1.3     Peptides as Targeting Entities 
As discussed, the targeting component can range between being a small 
molecule, peptide or antibody. Small molecules have several attractive qualities as 
targeting entities. They often have low molecular weight which allows access to many 
biological targets in the body. Small molecules are not easily detected and degraded by 
enzymes. They can be modified to produce many diverse compounds, but the synthesis 
may be difficult and time consuming and rarely leads to suitable imaging agents.10 
Another important shortcoming is the limiting number of radionuclides that can be 
incorporated into small molecules. Due to their low molecular weight, a bulky metal 
radionuclide, such as 68Ga, will often drastically lower the affinity. In this report, peptide-
based compounds are used as the targeting component for the development of 
molecular imaging probes. Peptides have many advantages over other targeting entities. 
 4 
 
Synthesis of peptides using automated solid-phase methods allow for easy and quick 
production of analogues to improve their stability and increase their half-life in biological 
systems.11 Moreover, peptides are able to withstand harsh chemical conditions such as 
radiolabelling conditions often requiring elevated temperatures and organic solvents.12 
Due to their higher molecular weight compared with small molecules, they are able to 
incorporate a large variety of radionuclides including the bulky metal radionuclides, 
without considerably affecting their binding affinity. Peptides have also been shown to 
possess high affinity for their target at nanomolar concentrations. In comparison to 
macromolecules, peptides have high tissue and tumour permeability and faster 
clearance rates due to their low molecular weights.11, 13 In addition, there are an 
increasing number of unnatural amino acids that are commercially available, thereby 
extending the chemical diversity of peptides. Due to the many benefits peptides provide 
over other targeting molecules, they are becoming more widespread in their use as 
imaging agents. This can be seen in the increasing number of peptide-based imaging 
agents in clinical trials. Some examples include [18F]Galacto-RGD, which is used to 
monitor tumour growth and metastasis14 (Figure 1.3) and 99mTc-UBI 29-41 (ubiquicidin), 
used to image infection.15  
                                     
Figure 1.3  [18F]Galacto-RGD, a PET imaging agent for oncologic applications14 
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The design of a suitable probe needs to account for biological stability, target affinity, 
target specificity and pharmacokinetic properties. One must design, synthesize and 
evaluate the lead peptides in vitro, and determine if further optimization is required. 
Biological evaluation may consist of competitive binding assays and serum stability 
studies. The peptides showing the best affinity and specificity to the target would move 
on to in vivo studies in small animal models. 
 
1.4 Radionuclide Labeling 
 Common labels used in molecular imaging are fluorescent dyes, radioisotopes, 
and paramagnetic agents, of which radioisotopes are used in nuclear imaging. The most 
common method to incorporate radionuclides is an indirect approach, where a 
radiometal chelator is conjugated onto the biological compound of interest and labelled 
with the radionuclide. Bifunctional metal chelators have recently gained much interest 
due to their high radiolabelling yields and good stability.16 The term bifunctional is used 
because they have a metal binding moiety function and also possess a chemically 
reactive functional group for covalent attachment to the targeting entity. The 
radiolabelling of the chelator can be carried out using either pre-labeling or post-labeling 
methodologies. In the first method, the radiolabeling is carried out initially, and 
afterwards the isotope-chelator complex is conjugated to the targeting entity. However, 
this method is not ideal because the purifications steps are time consuming and the 
radioisotopes used are short-lived.17 More commonly, the post-labeling approach is used 
in which the chelator is already conjugated to the peptide entity and the complex is 
radiolabeled. This method is more suited for the time sensitive radionuclide and often 
results in high yields.16 There are a variety of bifunctional chelators that are available to 
coordinate radiometals. These include DOTA, NOTA and DTPA (Figure 1.4).18-21  
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Figure 1.4 Examples of common bifunctional chelators that coordinate radiometals.              
A. DOTA  B. NOTA  C. DTPA 
 
 Linear polyamines such as DTPA (diethylenetriaminepentaacetic acid) can act as both a 
monofunctional and bifunctional chelator and has shown to coordinate a variety of 
radionuclides, such as 111In.22 The disadvantage of these anionic acyclic systems is that 
they tend to demonstrate low stability in vivo because of acid-promoted dissociation. A 
more stable alternative are macrocyclic bifunctional chelators such as DOTA (1,4,7,10-
triazacyclododocane-1,4,7,10-tetraacetic acid) and NOTA (1,4,7-triazacyclononane-
1,4,7-triacetic acid). They have been shown to form stable complexes with trivalent 
metals such as Ga, In, Y and Lu as well as some divalent metals. The high stability is 
usually associated with the slow dissociation reactions observed for the neutral 
complexes. Ideally, the chelator that is conjugated to a peptide should coordinate the 
radionuclide quickly and satisfactorily. Next, the complex should be stable to a pH range 
of 2-8 and in the presence of various cations found in serum [Ca(II), Zn(II)]. Finally, 
factors such as charge and lipophilicity should be considered. The choice of radionuclide 
is also important, and factors such as the half-life, availability and mode of decay have to 
be considered. The half-life should be long enough for the injection of the probe, its 
accumulation in the target tissues and ultimately its clearance and yet short enough to 
limit exposure to radioactivity.16 
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1.5 Imaging Modalities 
Two of the most common modalities in nuclear imaging are single-photon 
emission computed tomography (SPECT) and positron emission tomography (PET). 
Both modalities require only a small amount of the radioactive tracer which is then 
injected into the body to non-invasively monitor the target of interest. Currently, PET 
offers higher resolution and sensitivity whereas SPECT offers longer lived radioisotopes 
and lower costs.23 However, with advances in hardware and software, SPECT imaging is 
greatly improving and even surpassing small animal PET systems in spatial resolution.24, 
25 PET uses positron emitters and SPECT uses gamma emitters, though in both 
modalities gamma rays are detected.24 Some examples of common radionuclides used 
in PET and SPECT are listed in Table 1.1. 
Table 1.1 Common radioisotopes used in PET/SPECT imaging, along with their 
respective half-life and method of synthesis26    
                                                                                                                        
Radioisotope Half-life  Modality Method of Synthesis 
Oxygen-15 2.03 min PET cyclotron 
Carbon-11 20.3 min PET cyclotron 
Gallium-68 67.7 min PET generator 
Fluorine-18 109.8 min PET cyclotron 
Technetium-99m 6.02 hours SPECT generator 
Iodine-123 13.2 hours SPECT cyclotron 
Indium-111 2.83 days SPECT cyclotron 
Gallium-67 3.26 days SPECT cyclotron 
 
In PET, a positron-emitting isotope is introduced into the body conjugated to a 
biologically active molecule. The radioisotope emits a positron from its nucleus, which 
travels a short distance before it annihilates with a nearby electron (Figure 1.5).11 Upon 
annihilation, the mass of the proton and electron are converted into energy producing 
two simultaneous 511 keV gamma rays 180° from each other.26 These gamma rays are 
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detected by a set of adjacent detectors and the information gathered is used to construct 
an image.  
                          
Figure 1.5 Method of detection in PET 
 
In PET, there are three types of coincident events: random, scatter and true 
coincidences. Random coincidence occurs when photons from different nuclear decays 
are detected nearly simultaneously and are a source of undesirable background 
counts.27 In scattered coincidence, one or more photons change direction from a scatter 
before detection.27 Finally, true coincident events are the ones desired; anti parallel 
photons travel directly to the detectors. The distance travelled by the positron is known 
as the positron range and is proportional to the positron energy. It is one of the factors 
that affect the spatial resolution in PET.28 Other factors include patient movement, 
detector size and photon non-collinearity.29 Since radionuclides produce distinct positron 
energies, they also have varying flight distances, which in turn affect the spatial 
resolution in the image.30 This is especially significant in certain tissues, such as lung 
tissue, in which positron contribution was found to be three fold higher than in soft 
tissue.30 PET is very sensitive in the range of pM and is independent of the location 
depth of the tracer.9 There are a number of important implications that result from the 
high sensitivity, such as improved image quality, shorter and multiple scans and 
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improved temporal resolution.31 Additionally, PET radiotracers generally have shorter 
half-lives, so can be injected in higher activities to patients without causing greater 
radiation exposure in comparison to SPECT. All PET isotopes produce gamma rays of 
the same energy, consequently it is impossible to distinguish multiple probes containing 
different radioisotopes. There are many PET radionuclides used, such as 18F, 15O and 
11C, and 68Ga. As a result of the versatility of PET, there are a variety of PET 
radiotracers and clinical applications such as 18F-FDG, which is considered the golden 
standard in PET imaging and used in radiotherapy planning in various cancers such as 
neck, lung and head.16 
 SPECT is similar to PET, however, they differ in the type of radioisotope used. In 
SPECT, the gamma detector rotates around the patient and the gamma ray radiation is 
detected directly from the radionuclide. Directional information is obtained from the use 
of a collimator in front of the gamma camera which defines the angle of incidence of the 
emitted gamma rays.26 The loss of sensitivity and resolution compared with PET is 
caused by the collimator which results in low detection efficiency. Advances in the 
design of collimators such as multi-pinhole collimators have greatly improved the 
resolution and sensitivity of SPECT.24 Whereas the spatial resolution of PET is limited by 
physics, SPECT is only limited by technology and is constantly being enhanced.31 One 
important advantage of SPECT is that it allows for the simultaneous detection of multiple 
isotopes with varying gamma ray energies, such as in the study by Hashimoto et al  
using both 99mTc and 123I to image myocardial perfusion.32 This could potentially visualize 
multiple probes targeting distinct markers, and ultimately a single image of a cancer’s 
molecular expression profile.24 The most common radioisotopes used are 111In and 
99mTc. 99mTc has a half-life of 6 h which allows for the preparation, distribution to 
hospitals, accumulation in the target tissue, and collection of the image.23 The 
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radioactive decay can occur by a number of mechanisms such as electron capture in 
which a proton in the nucleus combines with an electron to form a neutron and a gamma 
ray.33 However, radionuclides such as technetium-99m undergo gamma emission 
whereby a nucleus in a high energy state relaxes over time via the emission of a gamma 
ray. The electromagnetic radiation is then detected by a gamma camera and an image is 
formed. 
 The use of either PET or SPECT is greatly dependent on the radionuclide and 
therefore the suitability of the probe and availability of the radionuclide and imaging 
equipment. 
 
1.6 Radionuclide Production 
Most short-lived radionuclides are neutron deficient and therefore can only be 
prepared in positive ion accelerators.34 In particular, cyclotrons are currently the 
preferred type of particle accelerator and are becoming much more common than in the 
past. The first cyclotron was built in 1930 with proof of particle acceleration provided in 
1931.35 The bombarding particles are typically protons, but can also be deuterons or 
helium particles.35 There are a large number of nuclear reactions that can be performed 
to produce various radioisotopes, including 18F, 111In and 68Ge.      
Table 1.2 Common radionuclides produced in a cyclotron and their nuclear reactions36                          
Radioisotope Half-life  Nuclear Reaction 
Fluorine-18 109.8 min 18O(p,n)18F 
Indium-111 2.8 days 111Cd(p,n)111In 
Germanium-68 272 days 69Ga(p,2n)68Ge 
 
The interest in quick and convenient radioisotope production lead to the 
development of generators. Generators are simple and convenient to use and provide 
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high yields of the daughter nuclide reproducibly on demand.37 They are shielded thus 
minimizing radiation exposure and their shipment is simple since they are quite sturdy. 
Generators are used for effective radiochemical separation of a daughter radionuclide 
formed by the decay of a parent radionuclide.38 The parent typically has a half-life much 
longer than the daughter to permit repeated separation of the daughter from the 
parent.37 Differences in the chemical properties of the two allow for the efficient isolation 
of the daughter radionuclide. There exist generator systems producing either positron 
emitters (68Ge/68Ga) or gamma emitters (99Mo/99mTc).38 In general, the parent 
radionuclide is adsorbed onto the column packing and decays into the daughter until an 
equilibrium is reached. This occurs within several half-lives of the daughter at which 
point the half-life of the daughter would appear to be the same as that of the parent. 
When the generator is eluted, the daughter would be eluted from the column, leaving the 
parent still adsorbed to the column because of their differing chemical properties. 
 
1.7 68Ge/68Ga Generator 
One very important generator system is the 68Ge/68Ga generator. The relatively 
long-lived 68Ge (half-life = 272 days) decays to short-lived 68Ga (half-life = 68 min), which 
ultimately decays to stable 68Zn.39 The chemical properties of Ge4+ and Ga3+ are 
sufficiently different to allow several methods for efficient separation. There are two main 
strategies used: organic matrices and inorganic oxides as matrices. One study used an 
organic polymer based on N-methylglucamine groups which was shown to rapidly and 
effectively adsorb 68Ge. After elution with trisodium citrate, the elution efficiency of 68Ga 
was 90% with 68Ge breakthrough less than 0.0004%.40 Unfortunately, organic polymers 
have low radiation stability compared to their inorganic competitors.41 The second 
strategy uses inorganic oxides such as Al2O3, SnO2 or TiO2. Though the alumina column 
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provides efficient separation, 68Ga is eluted as a 68Ga-EDTA complex.42 This leads to 
complicated and tedious synthesis of radiopharmaceuticals, thus generators providing 
68Ga3+ were developed. The SnO2 and TiO2 columns allow the elution of 
68Ga3+ using 
HCl. It has been shown that at a concentration of 0.1 M HCl, TiO2 shows the highest 
affinity for Ge (>95% adsorption) and lowest affinity for Ga (~0%) compared with Al2O3 
and SnO2.
41 Various methods have been developed to purify 68Ga3+ from 68Ge including 
the use of anion and cation exchange columns as well as Sep-Pak purification. The 
current approaches use different 68Ga species depending on the pH and concentration 
of eluent. The most popular method uses a cation exchange column, eluting with a 
HCl/acetone solution.43 It is a very reliable method that produces the product in high 
radiochemical purity, but uses organic solvents which requires quality control testing of 
the final products. More recent work has focused on a NaCl-based labelling procedure 
for DOTA conjugated peptides.43 It has eliminated the need for organic solvents yet 
maintains very high radiochemical purities. It is evident that generators, specifically the 
68Ge/68Ga generator, have many advantages in producing radionuclides. Their shipment 
is easy, are convenient to use and provide high yields of 68Ga reproducibly in high 
radiochemical purity.  
 
1.8 Chemistry of 68Ga  
68Ga has a convenient half-life of 68 minutes, which is long enough for 
experiments while minimizing the radiation exposure to the patient. It is an excellent 
positron emitter decaying 89% by positron emission and 11% by electron capture with a 
maximum positron energy of 1899 keV.44 The coordination chemistry of Ga3+ is well 
established and accordingly the chelator is designed to avoid in vivo transchelation of 
68Ga3+. Radiochemical yields are determined by the ability of the chelator to coordinate 
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Ga3+ from highly diluted solutions.45 As previously mentioned, common chelators are 
DTPA, DOTA and NOTA. Macrocyclic chelators will demonstrate selectivity for metal 
ions based how well the ion fits into the cavity.46 There are a wide array of applications 
that involve DOTA peptides including magnetic resonance imaging (Gd), nuclear 
imaging (111In and 68Ga) and therapeutic radiopharmaceuticals (90Y).47 Some examples 
of DOTA conjugated to peptides are comprised of DOTA labelled somatostatin 
analogues targeting neuroendocrine tumours (DOTA-octreotide),48, 49 GLP-1R agonists, 
(DOTA-exendin)50, 51 and various RGD peptides involved in angiogenesis.52  
The complexes formed should have high thermodynamic stability. The stability of 
the complexes tend to follow the hard-soft acid-base theory. Gallium is classified as a 
hard Lewis acid because of its high charge density and small ionic radius and therefore 
forms stable complexes with ligands that are hard Lewis bases, such as oxygen and 
nitrogen atoms.53, 54 Due to its small size (0.62 Å), it is often six-coordinate as a distorted 
octahedral. Gallium can also form four- and five-coordinate complexes, and be 
adequately stable in vivo. However, it is desirable to saturate the coordination sphere 
since unsaturated complexes often result in ligand exchange/hydrolysis.23  Under 
physiological conditions, the solution chemistry in aqueous media of gallium is solely 
represented by the oxidation state +3. An important consideration of the chemistry 
complexation of gallium is its pH dependent hydrolysis. Free Ga3+ is only stable under 
acidic conditions and can hydrolyze to insoluble trihydroxide [Ga(OH)3] in the pH range 
3.5-7. At physiological pH, soluble gallate ions [Ga(OH)4]
 − are formed.55 Hence, it is 
important for the optimization of pH levels and ligands for stable complexes to form 
during the reaction. Overall, the 68Ga coordinated macrocyclic chelators, such as DOTA, 
have shown high stability and biological inertness.55-57  
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68Ga is a PET radioisotope of great interest due to its convenient physical half-
life, accessibility and cost. There have been increasing examples in the literature of 68Ga 
labelled imaging agents for clinical applications. For instance, it has been used to 
visualize tumours,58 bone disorders,59 infection and inflammation such as 
Staphylococcus aureus infection and the detection of abscesses (68Ga-citrate),60 
diabetes, as well as many others.  
 
1.9 Thesis Rationale 
In this thesis we report on peptide-based probes that are developed into imaging 
agents to target two different receptors: receptor for HA mediated motility (RHAMM) and 
glucagon-like peptide 1 receptor (GLP-1R). In the first project, peptides derived from 
tubulin were synthesized and characterized in the hopes to mimic hyaluronan (HA), the 
natural ligand of RHAMM, a protein that is overexpressed in breast cancer tumours. In 
the past, HA has been labelled with radionuclides (125I and 99mTc) and MRI contrast 
agents (Gd3+) for its use as an imaging probe.61 Unfortunately, this poses several 
problems; the most important being its potential to target any of its numerous receptors 
(CD44, ICAM1, RHAMM, HARE), resulting in its non-specificity. Peptides as imaging 
agents provide a more promising alternative. The main advantages are the ability for the 
peptides to be designed to specifically target RHAMM and to not be recognized for HA 
clearance or degradation. Peptide ligands that show affinity and specificity for RHAMM 
were discovered through bioinformatics, biological assays and in vitro studies. In the 
second project, truncated analogues of GLP-1 will be synthesized and characterized, 
designed to target the glucagon-like peptide 1 receptor (GLP-1R) in the pancreas. The 
objective for both projects is to develop the lead peptides into imaging agents through 
the incorporation of a DOTA chelator and labelling with 68Ga. The imaging agents will be 
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evaluated via in vitro studies, followed by in vivo studies and biodistribution to assess the 
affinity of the probes to their respective receptors, RHAMM and GLP-1R. Ultimately, this 
dissertation aims to synthesize and characterize imaging agents that may potentially 
allow: 1) for the earlier, selective detection of primary and metastatic breast cancer as 
well as 2) the monitoring of pancreatic beta cell mass and the onset and progression of 
type 2 diabetes. 
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Chapter 2: Tubulin-derived Peptides as Imaging Agents 
to Image Highly Invasive Breast Cancer Subsets 
2.1    Introduction 
2.1.1    Hyaluronan, RHAMM and Breast Cancer  
Breast cancer is the most common cancer in women over the age of twenty and 
is a major cause of mortality worldwide. Figure 2.1 shows the number of prevalent 
cases for the leading types of cancer in Canada, with breast and prostate being the most 
prevalent for all three lengths of cancer duration.62                                                                                                                                                    
                                              
Figure 2.1 Number of prevalent cases of leading cancers, Canada, 2005 62  
Every day, 62 Canadian women are diagnosed and 14 Canadian women die of 
the disease.63 Breast cancer is a heterogeneous disease and as a result, it becomes 
challenging to manage. It contains subpopulations of aggressively invasive, highly 
proliferative tumour cells as well as slowly proliferating tumour initiating cells that are 
resistant to chemotherapy.64 Consequently, treatment regimens need to be personalized 
to individual patients in order to be successful. The current screening techniques are not 
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adequate. Mammography is one of the present screening methods for breast cancer, 
although the accuracy remains quite low.65 Often the primary tumour is too small to be 
clinically detected, and once it is large enough, it may have progressed into metastasis 
in some patients. Metastasis is the final step in tumour progression and is defined as the 
process of tumour cells leaving their niche, colonizing distant organ sites and forming 
secondary lesions.66 There is a great need for earlier detection methods in order to aid in 
the detection and treatment of metastatic breast cancer. Molecular imaging techniques 
can be very useful for screening, staging, response evaluation and guided surgery, 
radiotherapy and systemic treatment.67 
Tumour cells attach and migrate along the extracellular matrix which acts as a 
physical scaffold to help regulate cell motility, proliferation, invasion and metastasis.68 
Hyaluronan is a component of the extracellular matrix and its accumulation is a 
prognostic indicator of poor outcome in breast as well as other cancers. Hyaluronan 
(HA) is a negatively charged high molecular weight linear polysaccharide consisting of 
repeating units of D-glucuronic acid and N-acetyl glucosamine (Figure 2.2).69   
                                                                                 
Figure 2.2 Structure of hyaluronan69                                                                                     
HA is essential for proper cell growth, organ structural stability and tissue 
organization.70 It performs these cellular processes through its interaction with receptors 
on the cell surface, a family of proteins termed hyaladherins. There are three main 
groups of cell receptors for HA: cluster designation 44 (CD44), intracellular adhesion 
molecule-1 (ICAM1) and receptor for hyaluronan mediated motility (RHAMM). CD44 is 
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the best characterized HA receptor and is essential to the functioning of normal cells, but 
is also expressed in many malignant cell types.69, 71 It is part of the link module family of 
hyaladherins which all share a link fold defined by two α helices and two triple-stranded 
antiparallel β sheets.72 However, not all HA receptors contain a link module, such as 
RHAMM which bears no similarity in secondary structure to other HA binding proteins. 
Full length RHAMM is 85 kDa and its two predicted HA binding domains are contained 
within separate highly basic coiled regions that flank one another about a central 
groove.73 It binds to HA on the cell surface and regulates cell proliferation and promotes 
cell locomotion.74 The appealing quality of RHAMM is that it is poorly expressed in 
normal cells,75 transiently expressed following tissue injury and is highly over-expressed 
in metastatic cancers and implicated in tumour metastasis, specifically in cell motility and 
invasion.76 The HA binding motif of RHAMM has been identified near the carboxy-
terminus and consists of basic residues8. The region has a BX7B motif, where B is a 
basic residue and X is often a hydrophobic residue, but may be any residue excluding 
acidic.73 This motif is common to many proteins, so is not reliable for confirmation of HA 
binding. Nonetheless, it is evident that the main interaction between RHAMM and HA is 
likely based upon ionic interactions and the spatial distribution of the positively charged 
residues in RHAMM and the negatively charged carboxylate groups in HA to stabilize 
the complex. In addition, there are likely small contributions from hydrophobic 
interactions involving lipophilic patches on RHAMM and π-interactions between aromatic 
residues. Non-polar side chains may be involved in positioning the negative charges of 
the ligand so they interact with the corresponding positive charges on RHAMM.73 
Previously, HA was developed into an imaging agent and labelled with 99mTc. Under 
homeostatic conditions, it was found to target the HA receptor for endocytosis (HARE) 
which is located in the liver.61 The HARE receptor is responsible for the clearance of HA 
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and other glycosaminoglycans.77 The largest issue with HA as an imaging agent is that it 
has the potential to bind to any of the HA receptors, and not specifically to RHAMM. 
Moreover, HA would be rapidly degraded by hyaluronidase enzymes (Hyal-1, Hyal-2, 
PH-20).78, 79 In order to develop a RHAMM specific imaging agent that will not be 
degraded by hyaluronidases, new ligands are desired.  
 
2.1.2    Tubulin-Derived Peptides Targeting RHAMM 
 In addition to the cell surface, RHAMM is also reported to localize in the 
cytoplasm in a series of human breast cancer and various rodent tumour cell lines.80 It 
localizes at the perinuclear microtubule network during interphase and appears to 
control proliferation and gene expression required for cell cycle progression.77 This 
localization to microtubules is mediated by the carboxy terminus of RHAMM. 
Microtubules are structures that maintain cell morphology and mediate functions such as 
mitosis and locomotion, which require interaction between microtubules and microtubule 
associated proteins (MAPs).81 Microtubules consist of αβ-tubulin dimers whose carboxy 
terminal region contains a hypervariable carboxy terminal tail (CTT) composed of acidic 
residues. It is especially rich in glutamic acid residues and is likely to project outward 
from the rest of the molecule because of the electrostatic repulsion among the high 
negative charge density.82 The three-dimensional structure of the globular domain of 
microtubules has been determined by x-ray crystallography, however, the 
heterogeneous C-terminal region has only been predicted by computer modeling.83 Both 
α- and β-tubulin consist of various isotypes that differ in their amino acid sequence and 
cellular and tissue distribution.84 For the assembly of microtubules to occur, the CTT 
must first be removed from tubulin by the serine protease, subtilisin, which cleaves the 
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C-terminal 10-20 amino acids of α- and β-tubulin.85, 86 MAPs are positively charged and 
bind to the negatively charged CTT region of α- and β- tubulin.87  
 
2.1.3    Rational Approach for the Design of Peptides 
 In the design of peptide mimics, there are two broad approaches. The first is the 
use of a random combinatorial peptide library and the second is a rational based design. 
In this case a rational approach was used since the structure of the target is known. This 
approach can be further specified into a ligand-based design. In this design, targeting 
entities are developed with regard to the structure of the target receptor and what 
ligands may potentially bind to it.88 In order to predict potential ligands that will target the 
choice receptor, often bioinformatics is used. As a result, information regarding the 
target protein structure/sequence is required for this approach. Bioinformatics is a very 
useful discipline that uses many areas of mathematics, computer science and 
engineering to process biological data.89 Sequence alignment tools such as BLAST 
(basic local alignment search tool) allow for protein sequences to be screened to large 
online databases and identify proteins that show a high level of sequence similarity.90 
Programs, such as ClustalX2, can make pairwise comparisons and calculate homology 
between the sequences found using BLAST and the target sequence.91 The Clustal 
series provide robust, portable programs that afford biologically accurate alignments 
within a reasonable time.92 
Using BLAST and ClustalX2, database searches between RHAMM and 
microtubule binding domain of MAPs revealed only a moderate sequence homology of 
17-24% to the HA binding domain of RHAMM.93 More importantly, both RHAMM and 
MAPs have a stretch of basic residues. Furthermore, the secondary structures of the 
tubulin binding sites of MAPs and hyaluronan binding site of RHAMM has the same 
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degree of helicity and both could be classified as a basic-zipper domain.94 Since MAPs 
show direct binding to CTTs of tubulin, the hypothesis is that RHAMM should interact 
with synthetic peptides representing the CTTs of tubulin subtypes. The objective of this 
thesis is for the discovery of low molecular weight ligands that strongly and specifically 
target RHAMM for diagnostic and therapeutic purposes. Our goal is to develop a 
peptide-based imaging agent that mimics hyaluronan (HA) to address two obstacles in 
clinical studies: early detection and tumour cell heterogeneity. A molecular imaging 
probe that strongly targets the HA receptor RHAMM will permit the selective detection of 
highly tumorigenic progenitor cells in primary and metastatic carcinoma. Furthermore, 
the non-invasive imaging of RHAMM post-chemotherapy has the potential to determine 
residual disease. A second goal is to improve the in vivo stability of the peptides and 
potentially the affinity to RHAMM by incorporating unnatural amino acids. 
 
2.2    Previous Research 
 Various peptides were synthesized for this study based off of tubulin fragments 
taken from the CTT region or directly flanking it (Table 2.1).93 Peptides were chosen 
based on the most common tubulin isoforms, as well as the most acidic region of the 
peptide. The seventeen tubulin derived peptides were evaluated using surface plasmon 
resonance (SPR). For this experiment, RHAMM was immobilized to the SPR sensor chip 
surface, and the tubulin peptides were injected and passed across the RHAMM surface. 
The real time association and dissociation interactions of each peptide to RHAMM are 
detected and reported as sensograms. The resulting sensograms measure the affinity of 
each individual peptide to the HA binding region of RHAMM.93 The results highlight the 
discovery of six high affinity peptides (Table 2.2). 
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Table 2.1 Sequences from fragments of various tubulin isoforms93 
Sequence Tubulin Fragment Type 
DSADGEDGEEY αIc (438-449) CTT 
VEGEGEEEGEEY αIa (440-451) CTT 
SVEAEAEEGEEY αIIIc (439-450) CTT 
IDSYEDEDEGEE αIVa (437-448) CTT 
DSFEEENEGEEF αVIII (438-449) CTT 
LEKDYEEVGVDS αIa (428-439) H12 
GEFSEARDMAA αIa (416-427) H12 
FVHWYVGEGMEE αIa (404-415) CTT 
GEFEEEEGEDEA βIIa (434-445) CTT 
EEDFGEEAEEEA βIa (433-444) CTT 
GEFEEEAEEEVA βIV (433-444) CTT 
EAFEDEEEEIDG βVI (435-446) CTT 
SNMNDLVSEYQQ βIIIa (413-424) CTT 
FTEAESNMNDLV βIIIa (408-419) CTT 
RPDYISWGTQEQ γI (440-451) CTT 
VQQLIDEYHAAT γI (428-439) CTT 
DNPDEMDTSREI γI (416-427) CTT 
Table 2.2 Average KD values of peptides with affinity for RHAMM from SPR screen
93 
Sequence Average KD (nM) 
SVEAEAEEGEEY-NH2 331.1 ± 24.5 
GEFEEEAEEEVA-NH2 130.0 ± 12.9 
VEGEGEEEGEEY-NH2 24.2 ± 0.4 
EEDFGEEAEEEA-NH2 32.6 ± 1.1 
EAFEDEEEEIDG-NH2 211.3 ± 8.6 
FTEAESNMNDLV-NH2 30.2 ± 1.5 
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In order to determine the selectivity of the peptides to the HA binding domain of 
RHAMM, a competitive ELISA was performed. The peptides were labelled with FITC on 
the N-terminus as shown in Figure 2.3. Binding is thought to occur at the C-terminus so 
all modifications were done on the N-terminus.  
 
 
Figure 2.3 Peptide modified with aminohexanoic acid linker and fluorescein 
isothiocyanate onto the N-terminus 
 
Fluorescein-labelled peptides are added to ELISA plates containing immobilized 
RHAMM and increasing concentrations of HA are added. If there is a competition for the 
binding site, a concentration dependent decrease in fluorescence will occur as the 
concentration of HA increases and displaces the peptides. The results indicate that four 
of the candidates were able to compete with HA for binding.93 
                  
Figure 2.4 ELISA assay of fluorescein-labelled peptides immobilized to recombinant 
RHAMM and CD44. Displacement of peptides by HA were seen for RHAMM, but not 
CD44 93 
 24 
 
To confirm the specificity of the tubulin peptides to RHAMM, their affinities were tested 
against both RHAMM and CD44, a second receptor for HA (Figure 2.4).93 There is 
evidence that many of the peptides are interacting with RHAMM, but not CD44. From the 
results, three candidate peptides were chosen based on their specificity and high affinity 
to the HA binding domain of RHAMM (Figure 2.5). 
1 VEGEGEEEGEEY-NH2  KD = 24 nM 
2 EEDFGEEAEEEA-NH2  KD = 32 nM 
3 FTEAESNMNLDV-NH2  KD = 30 nM 
 
Figure 2.5 Selective, high-affinity ligands for RHAMM 
 
2.3 Project Goal 
It is now proposed that these peptide ligands, when modified to incorporate a positron-
emitting isotope, will be suitable for the non-invasive imaging of RHAMM expression in 
vivo using PET. Thus, the molecular imaging probes are being developed in order to aid 
in the early and selective detection of tumorigenic progenitor cells in primary and 
metastatic carcinoma by specifically targeting RHAMM. 
2.4 Results and Discussion 
2.4.1 Synthesis of Imaging Agents 
The design of peptide-based molecular imaging probes often involves the 
addition of a metal chelation system. A typical compound used to generate these 
chelation systems is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). 
In order to modify the peptides with DOTA, each peptide was first synthesized containing 
a linker, aminohexanoic acid (Ahx), on the N-terminus. The purpose of the linker is to 
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reduce any steric effects imposed by the macrocyclic DOTA ring on the binding of the 
peptide chain. The peptides were synthesized using standard Fmoc solid phase peptide 
synthesis (SPPS) methods either manually or with an automated synthesizer (Scheme 
2.1).  
              
Scheme 2.1 Solid phase peptide synthesis  
N-Fmoc removal was achieved using 20% v/v piperidine in DMF, and the Kaiser test is 
performed to confirm the presence of free primary amino groups.95 Amino acids with 
reactive side chains were protected with acid labile orthogonal protecting groups such as 
OtBu and tBu. A representative synthetic route is described in Scheme 2.2, illustrating 
the preparation of DOTA-Ahx-peptide-NH2. Typically in our lab when DOTA is desired as 
a chelator, it is bought commercially in the form of DOTA-tris-t-butyl ester and is coupled 
to the peptide under normal coupling conditions. However, this is usually quite expensive 
and a much cheaper alternative is to synthesize DOTA directly onto the peptide. Since 
the binding to RHAMM is thought to occur at the C-terminus and modifications are made 
at the N-terminus of the peptide, the addition of the chelator during solid-phase synthesis 
was possible. Once the linker was coupled to the peptide (4), it was modified with a 
DOTA chelator in a three step process. The first step uses DIC to couple bromoacetic 
acid to the peptide (5). The next step is to react 5 with cyclen, displacing the Br leaving 
group, and producing 6. Finally, t-butyl bromoacetate is reacted with 6, then the peptide 
is cleaved from the resin and all protecting groups removed, including the t-butyl groups 
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of DOTA, using trifluoroacetic acid (TFA) to produce the DOTA peptides, 7a, 8a and 9a. 
Figure 2.6 shows the HPLC and MS traces for 7a and 9aii while the values for the purity 
of all the peptides along with their respective ESI-MS characterization are given in Table 
2.3. 
  
 
 
 
 
 
 
 
 
 
 
Scheme 2.2 Synthesis for the addition of DOTA chelator to a peptide 
 
 peptide = VEGEGEEEGEEY (7a)                                                                                                 
                = EEDFGEEAEEEA (8a) 
                = FTEAESNMNDLV (9a) 
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Figure 2.6 A. HPLC trace and MS spectra for 7a B. HPLC trace and MS spectra for 9a.ii 
 
Table 2.3 Analysis of synthesized DOTA peptides using UHPLC and ESI-MS 
Compound Peptide Calculated m/z Observed m/z Purity* 
[M+2H]
2+
 
 
7a 
 
DOTA-Ahx-VEGEGEEEGEEY-NH2 
 
927.4003 927.4018 
 
>99% 
 
8a 
 
DOTA-Ahx-EEDFGEEAEEEA-NH2 941.3978 941.3815 
 
>95% 
 
9a.i 
 
DOTA-Ahx-FTEAESNMNDLV-NH2 934.4413 934.4376 
 
>95% 
 
9a.ii 
 
DOTA-AEEA-FTEAESNMNDLV-NH2 950.4362 950.4348 
 
>95% 
 
7b 
 
69/71
Ga-DOTA-Ahx-VEGEGEEEGEEY-NH2 
 
961.3524 
 
961.3503 
 
>99% 
 
8b 
 
69/71
Ga-DOTA-Ahx-EEDFGEEAEEEA-NH2 
 
975.3499 
 
975.3498 
 
>90% 
 
9b 
 
69/71
Ga-DOTA-AEEA-FTEAESNMNDLV-NH2
 
 
984.3882 
 
984.3896 
 
>90% 
*Purity is determined through the integration of the area under the curve                                                                                                                              
Before a radionuclide is incorporated, it must first be characterized with a cold, 
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non-radioactive isotope. Two of the candidate peptides (7a and 8a) were labeled 
with cold 69/71Ga (Scheme 2.3).  
 
 
 
 
                                                                       
Scheme 2.3   Synthesis for the incorporation of cold 69/71Ga to a DOTA peptide 
   
A buffer is needed to keep the desired pH of 4 since under basic conditions, it will form 
insoluble gallate ions [Ga(OH)4-].55 9a.i was insoluble in the buffer, and as a result was 
unable to be cold labeled. Instead, a hydrophilic linker was added in place of 
aminohexanoic acid in hopes of increasing the solubility in aqueous buffer. The peptide 
containing the mini PEG linker, AEEA (2-[2-(2-aminoethoxy)ethoxy]acetic acid), 9a.ii 
was still not soluble and needed a 1:1 ratio ethanol: sodium acetate buffer in order to 
fully dissolve. After the reaction was complete for 7a, 8a and 9a.ii, the mixture was 
cooled and was purified by a C18 RP Sep-Pak. The peptides, 7b, 8b and 9b were 
characterized using LC/MS (Table 2.3).  
 
2.4.2 68Ga labelling 
Since the cold 69/71Ga labeling was successful, the DOTA peptides, 7a and 8a were then 
radiolabelled with 68Ga using HEPES buffer and heated at 80°C for 30 minutes. The 
radiolabelling of compounds was carried out using an Eckert and Ziegler 68Ge/68Ga 
generator connected to a series of synthesis modules, which are remotely controlled by 
the user via a process computer (Figure 2.7). A graphical representation of the program 
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used for radiolabelling peptides using 68Ga is shown in Figure 2.8 as well as the various 
components in Table 2.4. 
                       
Figure 2.7 A. Eckert and Ziegler modular lab automated synthesis unit for 68Ga labelling; 
B. Polymeric strata used as part of the automated synthesis unit for 68Ga labelling 
 
 
Figure 2.8 Schematic of a program designed for the 68Ga-radiolabelling of peptides 
A B 
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Table 2.4 Description of components used in Figure 2.8 
Component Symbol 
Vial 
        
Squeeze pump 
      
Cation exchange 
column/sep pak         
Heating reaction vial 
      
Three-way valves 
     
Sterile filters 
     
 
All solutions in this system, with the exception 0.1 N HCl which is transferred by a 
pressure pump, are transferred via pressure variance. First, gallium-68 is eluted from the 
generator using a squeeze pump and 3 mL of 0.1 N HCl (vial 1-1). This eluate, which 
may contain impurities such as 68Ge breakthrough is then loaded onto a strong cation 
exchange column for initial purification. Gallium-68 is then eluted out of the cation 
exchange cartridge using 0.5 mL of 0.05 N HCl in 98% acetone (vial 1-3), and carried to 
the reaction vessel containing the peptide dissolved in buffer. After the reaction is 
complete, the mixture is passed through a C18 light Sep Pak for purification. A 2 mL 
aliquot of water is then passed through this cartridge to elute free Ga-68. The final 
product is isolated and eluted using EtOH into a clean glass vessel. A small sample of 
the final product is diluted with water prior to analysis by HPLC. 
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Peptides 7a and 8a were successfully radiolabelled with the positron emitting 
isotope 68Ga using 100 µg of precursor, in a radiochemical yield of 67% and 65%, 
respectively and radiopurity of >99% (Table 2.5: 7c., 8c). It is impossible to purify using 
HPLC because the unlabelled precursor elutes very close compared to the gallium 
coordinated peptide, as seen in Figure 2.9, and is the same case for all the peptides.  
 
 
Figure 2.9 Stacked HPLC traces of the precursor, 7a, cold 69/71Ga coordinated peptide, 
7b, and 68Ga labelled peptide, 7c 
 
In order to improve specific activity and still obtain approximately the same 
radiochemical yield, experiments were performed to decrease the amount of precursor 
needed. It was found that the amount of precursor can be decreased to 10 µg while still 
obtaining reasonable yields. In this method, the automated system was not used, and 
instead the peptide was reacted with 68Ga manually. The reaction took place at 90°C for 
10 minutes. After the reaction, it was passed through an equilibrated C18 RP light Sep-
Pak, flushing with water into the waste and ethanol to elute the product, respectively. 7a 
was reacted manually with 68Ga successfully to produce 7c in a radiochemical yield of 
60 %, an estimated specific activity of >14 GBq/µmol and radiopurity of >99% (Table 
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2.5: 7c). Optimization of the labelling procedure led to using 20 µg of precursor, resulting 
in an improved specific activity of >19 GBq/µmol and radiochemical yield of 75%. 
Similarly, 9a.ii was labelled with 68Ga manually and a very high radiochemical yield of 
91% was obtained using 20 µg of precursor and a good estimated specific activity of >30 
GBq/µmol.     
 
Table 2.5 Optimization of labelling conditions for the radiolabelled peptides 
 
68
Ga-DOTA-Ahx-
VEGEGEEEGEEY-NH2 
68
Ga-DOTA-Ahx-
EEDFGEEAEEEA-NH2 
68
Ga-DOTA-AEEA-
FTEAESNMNDLV-NH2
 
Compound 
number 
                    
                   7c 
 
8c 
 
9c 
Precursor 
Amount (ug) 
 
100 
 
10 
 
20 
 
100 
 
10 
 
20 
Specific 
Activity 
(GBq/µmol) 
 
 
>2 
 
 
>14 
 
 
>19 
 
 
>2 
 
 
>5 
 
 
>30 
RCY (%) decay 
corrected (d.c.) 
 
67 
 
60 
 
75 
 
65 
 
11 
 
91 
Radiopurity (%)  
>99 
 
>99 
 
>99 
 
>99 
 
>99 
 
>99 
 
  
2.4.3 In Vivo Studies 
The first in vivo experiment was performed with the radioactive compound 7c (using 10 
µg of precursor), which was injected through the tail vein of xenograft mice with MDA-
MB-231 tumours in the fourth mammary gland. MDA-MB-231 cells are a human breast 
cancer cell line that has been shown to overexpress RHAMM. Afterwards, biodistribution 
studies were performed by Dr. Lihai Yu, but were inconclusive and further evaluation 
was required. For the next attempt of in vivo studies, the tumour model was changed to 
LR21 cells. It is a fibroblast line, specifically 10T1/2 cells, transfected with the v4 isoform 
of RHAMM. A pilot study was performed with three xenograft mice with tumours injected 
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into the flank. Since the radioactive compound 9c (20 µg of precursor) was resulting in a 
better specific activity than 7c, it was used for the study and was injected through the tail 
vein of the mice. The sacrifice of the mice followed by biodistribution was performed by 
Dr. Lihai Yu two hours after injection. The results demonstrate that the probe did not 
target the tumour. All organs showed no significant uptake excluding the kidneys and 
tail, where the probe was excreted and injected, respectively. It is evident that the 
probes are not adequate imaging agents in vivo in the models tested. It is possible the 
peptides may not be stable in vivo and are being degraded.    
 
2.4.4 Design of Peptide Analogues 
In order to optimize the affinity of the peptides for RHAMM, we performed an 
alanine scan to determine which residues are critical for peptide-receptor interaction. 
The technique uses the amino acid, alanine, to substitute each residue in the sequence 
sequentially and the fluorescence is measured. Peptides were synthesized with a linker 
and a fluorescein label attached to the N-terminus. The alanine scans for peptides 21 
and 22 were previously performed in which the important amino acids are indicated 
(Figure 2.10). The remaining peptide, 2, needed to be synthesized with FITC and the 
linker as well as its analogues with the sequential substitution of alanine. However, the 
scan showed no key amino acids and was re-tested for confirmation. Table 2.6 shows 
the sequence of the eleven synthesized peptides as well as their calculated and 
observed masses.  
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Figure 2.10 Alanine scans for peptides FTEAESNMNDLV (left) and VEGEGEEEGEEY 
(right). The stars represent the sequences where Ala has replaced a key amino acid 
 
Table 2.6 Mass spectrometric analysis of synthesized peptides 
Compound Peptide Calculated  Observed  Purity 
[M+2H]
2+
 
10 Fitc-Ahx-EEDFGEEAEEEA-NH2 942.8 943.6  >95% 
11 Fitc-Ahx-AEDFGEEAEEEA-NH2 913.8 914.4 >95% 
12 Fitc-Ahx-EADFGEEAEEEA-NH2 913.8 914.5 >95% 
13 Fitc-Ahx-EEAFGEEAEEEA-NH2 920.8 921.4  >95% 
14 Fitc-Ahx-EEDAGEEAEEEA-NH2 904.8 905.4  >95% 
15 Fitc-Ahx-EEDFAEEAEEEA-NH2 949.9 950.6  >90% 
16 Fitc-Ahx-EEDFGAEAEEEA-NH2 913.8 914.5 >95% 
17 Fitc-Ahx-EEDFGEAAEEEA-NH2 913.8 914.5 >95% 
18 Fitc-Ahx-EEDFGEEAAEEA-NH2 913.8 914.4 >90% 
19 Fitc-Ahx-EEDFGEEAEAEA-NH2 913.8 914.4 >95% 
20 Fitc-Ahx-EEDFGEEAEEAA-NH2 913.8 914.4 90% 
 
After the alanine scans were prepared for peptides 21 and 22, truncation studies must 
be designed and performed to ensure the peptides contain the key amino acids that 
were shown in Figure 2.12. For initial studies, two truncated versions of peptide 20 and 
one version of peptide 21 were synthesized. In addition to the truncated peptides, 
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positive and negative controls were also synthesized, and will be evaluated using ELISA 
with RHAMM acting as the blank (Table 2.7).  
 
Table 2.7 Alanine scan results and subsequent truncated sequences and controls that 
will be evaluated using ELISA 
 
# Peptide Sequence Important 
Amino Acids 
Truncated 
Sequence 
Controls 
21 FITC-Ahx-FTEAESNMNDLV-NH2 *TE*ES**ND** TEAES-NH2 
 
ESNAND-NH2 
-ve: SAETE -NH2        
(scrambled sequence) 
-ve: NDASEN-NH2  
(scrambled sequence) 
+ve: FTEAESNMNDLV-NH2 
22 FITC-Ahx-VEGEGEEEGEEY-NH2 *E*E**EEGE*Y EEGEAY-NH2 -ve: EYAEGE -NH2  
(scrambled sequence) 
+ve: VEGEGEEEGEEY-NH2 
 
Unfortunately, purified recombinant RHAMM protein is needed for the ELISA and was 
not synthesized in time so there are currently no results to report. 
Since it is unknown how truncation affects the affinity of the peptides, 
alternatively amino acid modifications were performed. This was done in order to further 
optimize the affinity and help improve the in vivo stability of the peptides through the use 
of unnatural amino acids. The important amino acids, determined from the alanine 
scans, were individually replaced by unnatural amino acids and bioisosteres. According 
to Burger, bioisosteres are defined as compounds that possess near-equal molecular 
shapes and volumes, approximately the same distribution of electrons and exhibit similar 
physical properties.96 The objective of the replacement is to enhance either the desired 
physical or biological properties without altering the chemical structure significantly. 
There are classical and nonclassical bioisosteres. Classical bioisosteres involve 
structurally simple groups such as monovalent atoms (D, F), divalent atoms (C=O, C=S) 
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or ring equivalents. In contrast, nonclassical bioisosteres are structurally distinct, and 
often exhibit different steric and electronic properties.96  
In the literature, there are several examples of bioisosteres of carboxylic acids 
and amides,96-99 however, due to time constraints it was opted to only pursue 
commercially available compounds. As a result, many of the more common and 
interesting bioisosteres, such as tetrazoles, sulfonamides, oxazoles and a 
trifluoroethylamine moiety were not used. Instead, an acidic sulfonate was used to mimic 
the carboxylic acid of glutamic and aspartic acid in the form of cysteic acid. To mimic 
asparagine, a couple different replacements were attempted. The first replacement 
utilized an ester instead of the amide (Asp-OMe-OH). In the second replacement, the 
asparagine was replaced with a thiazole (Ala-4-thiazoyl-OH). Glycine, being structurally 
very simple could not be changed very much except for the addition of methyl 
(methylene) groups at varying positions. Some of the more obvious replacements were 
used for serine and threonine such as replacing the hydroxy group with a methoxy or 
adding a methyl group onto the peptide backbone. Similarly, the main replacements for 
tyrosine were replacing the hydroxy group with various other groups such as an amine 
or methoxy as well as changing the aromatic group to a bulkier naphthalene.  
The amino acids considered not to be critical were individually replaced with 
amino acids containing various groups such as an aromatic or an alcohol to determine if 
the affinity can be improved. Furthermore, each amino acid, critical or noncritical, was 
replaced with its D-amino acid counterpart to incorporate unnatural amino acids into the 
sequence and vary its conformation. Table 2.8 lists all of the critical amino acid 
replacements and Table 2.9 lists all other amino acid replacements for the peptides 1 
(VEGEGEEEGEEY) and 3 (FTEAESNMNDLV).     
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Table 2.8 Replacements of critical amino acids for peptides 1 and 3 
Amino Acid Bioisosteric Replacement 
 
Amino acid 
replacement 
Ser, Thr OH to OMe (only Ser) 
β-HSer, β-HThr 
Me to peptide backbone 
D-Ser 
D-Thr 
Asn Amide to: ester, thiazole,  Gln 
D-Asn 
Glu, Asp COOH to sulfonate D-Glu, D-Asp 
Tyr  OH to: F, OMe, NH2, NO2 
Nal 
Phe 
D-Tyr 
9
Gly  β-Ala 
Aib 
D-Ala 
 
Table 2.9 Replacements of noncritical amino acids for peptides 1 and 3 
Amino Acid Amino Acid Replacement 
Phe Tyr, Nal, Ala, Ser, Asp 
D-Phe 
Ala Aib, Ser, Phe 
D-Ala 
Asn Gln, Asp, Leu, Tyr 
D-Asn 
Met Val, Phe, Nle, Thi 
D-Met 
Leu Val, Ser, Phe 
D-Leu 
Val Ala, Ile, Phe, Asp 
D-Val 
3,5
Gly Ala, Aib, β-Ala 
D-Ala 
Glu Ala, Asp, Gln, Thr, Phe 
D-Glu 
 
The peptides were synthesized on tentagel S NH2 resin on the tip synthesis workstation 
(Biotage, Uppsala, Sweden). The tip station allows for the synthesis of many peptides 
simultaneously in small amounts.  The tip module offers wells for 96 peptides and the 
amino acid rack offers space for 25 different amino acids. Unfortunately, the synthesis 
had to be broken into three separate syntheses due to the limited rack space (25 slots) 
 38 
 
to hold the number of unnatural amino acids (28) and natural amino acids (12) adding to 
a total of 40 amino acids. For the screening of the peptides against RHAMM, it is 
necessary that they are stable against the acidic conditions. Tentagel resin was used 
instead of Rink amide resin because of the PEG linker it possesses and the ability for 
biological evaluation in aqueous media. Tentagel contains a free amine and forms a 
stable amide bond with the peptide. Therefore the peptides are deprotected during the 
acidic cleavage conditions, but remain on resin. All the peptides synthesized for this 
experiment are shown in Table 2.10, including the positive control peptides with no 
changes made and a scrambled version of each as the negative controls. Before the 
analogues were synthesized, several test peptides were synthesized on Rink amide 
resin in order to confirm that an acceptable purity is obtained since this will be the first 
time the tip synthesizer is used. One of the amino acids, Fmoc-cysteic acid-OH had to 
first be modified before further use since in its commercial form, it is not soluble in DMF 
or NMP (N-methyl-2-pyrrolidone).100 Since it is unknown whether the commercial form 
was the free acid or possessed a Na+ counterion, we erred on the cautious side and 
dissolved the amino acid in water and ran the solution through an ion exchange column 
(Amberlite IR-120H). It was then lyophilized and the free acid was treated with 1.05 eq of 
40% tetrabutylammonium hydroxide (aq) and was lyophilized.100 The resultant white, 
glassy solid was highly soluble in DMF and was used as part of the synthesis of the 
peptides involving cysteic acid on the tip workstation. 
 
 
 
Scheme 2.4 The synthesis of the tetrabutylammonium salt of cysteic acid 
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Table 2.10 Peptides synthesized on tip synthesizer for screen. Resin was tentagel S 
NH2 (90 μm). Scale = 0.0005 mmol 
 
 FTEAESNMNDLV (+ve control) 
SVNLEFMANEDT (- ve control) 
VEGEGEEEGEEY (+ve control) 
GYGEEEEVEEGE (- ve control) 
D-amino acids fTEAESNMNDLV 
FtEAESNMNDLV 
FTeAESNMNDLV 
FTEaESNMNDLV 
FTEAeSNMNDLV 
FTEAEsNMNDLV 
FTEAESnMNDLV 
FTEAESNmNDLV 
FTEAESNMnDLV 
FTEAESNMNdLV 
FTEAESNMNDlV 
FTEAESNMNDLv 
vEGEGEEEGEEY 
VeGEGEEEGEEY 
VEgEGEEEGEEY 
VEGeGEEEGEEY 
VEGEgEEEGEEY 
VEGEGeEEGEEY 
VEGEGEeEGEEY 
VEGEGEEeGEEY 
VEGEGEEEgEEY 
VEGEGEEEGeEY 
VEGEGEEEGEeY 
VEGEGEEEGEEy 
FTEAE(Ser-OMe)NMNDLV   
FTEAE(β-HSer)NMNDLV 
F(β-HThr)EAESNMNDLV 
FTEAE(N-Me-Ser)NMNDLV 
F(N-Me-Thr)EAESNMNDLV 
VEGEGEEEGEE(Phe-4-F) 
VEGEGEEEGEE(TyrMe) 
VEGEGEEEGEE(Phe-4-NH-Boc) 
VEGEGEEEGEE(Phe-4-NO2) 
VEGEGEEEGEENal 
VEGEGEEEGEEF 
FTEAESNMQDLV 
FTEAESNM(D-OMe)DLV 
FTEAESNM(A-thiazoyl)DLV 
VEGEGEEEAibEEY 
VEGEGEEE(β-Ala)EEY 
FT(CA)AESNMNDLV 
FTEA(CA)SNMNDLV 
FTEAESNMN(CA)LV   CA=cysteic acid 
V(CA)GEGEEEGEEY 
VEG(CA)GEEEGEEY 
VEGEGE(CA)EGEEY 
VEGEGEE(CA)GEEY 
VEGEGEEEG(CA)EY 
YTEAESNMNDLV 
VTEAESNMNDLV 
STEAESNMNDLV 
DTEAESNMNDLV 
NalTEAESNMNDLV 
VEAEGEEEGEEY 
VEGEAEEEGEEY 
VEAibEGEEEGEEY             VEGEAibEEEGEEY 
VEβ-AlaEGEEEGEEY          VEGEβ-AlaEEEGEEY 
FTEAibESNMNDLV 
FTESESNMNDLV 
FTEFESNMNDLV 
FTEβ-AlaESNMNDLV 
IEGEGEEEGEEY 
TEGEGEEEGEEY 
FEGEGEEEGEEY 
 
FTEAESQMNDLV  
FTEAESDMNDLV 
FTEAESLMNDLV 
FTEAESYMNDLV 
VEGEGDEEGEEY 
VEGEGQEEGEEY 
VEGEGTEEGEEY 
VEGEGYEEGEEY 
FTEAESNVNDLV 
FTEAESNSNDLV 
FTEAESNFNDLV 
FTEAESNENDLV 
FTEAESNNleNDLV 
FTEAESNThiNDLV 
VEGEGEEEGEAY 
VEGEGEEEGEVY 
VEGEGEEEGESY 
VEGEGEEEGEDY 
VEGEGEEEGEFY 
 
FTEAESNMNDSV 
FTEAESNMNDFV 
FTEAESNMNDVV 
 
FTEAESNMNDLA 
FTEAESNMNDLT 
FTEAESNMNDLY 
FTEAESNMNDLE 
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2.4.5 Library Screening 
 One method in discovering novel peptides is the one-bead one-compound 
(OBOC) approach. In an OBOC combinatorial library, the peptides consist of random 
sequences and are tethered to tentagel resin beads. Typically, the beads are incubated 
with fluorescent cells that express the protein of interest. Afterwards, the beads are 
screened using a plate reader or a biosorter to identify hit peptides with cells attached. 
This approach has been used to discover many novel peptides.101 In my case, the 
peptide library will consist of known rather than random sequences as in OBOC libraries. 
However, the same cell-based screening approach will be attempted to discover novel 
high affinity peptides. Before my peptide analogues were synthesized, the conditions for 
the on-bead cell binding assay needed to be determined. The assay was attempted with 
two of the lead peptides, 1 and 3 as well as scrambled versions of the peptides and 
beads with no peptide attached for negative controls in various cell lines that 
overexpress RHAMM. The three cell lines used in this experiment were the human 
breast cancer cell line MDA-MB-231 as well as a fibroblast line, 10T1/2 cells, that were 
transfected with RHAMM-V4, which can be further divided into two cell lines: LR21 and 
10V4. The LR21 cells are a clonal cell line and have a homogenous level of RHAMM 
overexpression. The 10V4 cells are a mixture of clones, so they will have the cDNA 
integrated into different parts of the genome. Therefore the two exhibit the same 
characteristics, but LR21 are typically more aggressive compared with 10V4. A knockout 
(KO) cell line was also used which does not express any RHAMM, to act as a negative 
cell line. In all cases, the cells were dissociated, counted and approximately 200,000 
cells were added to non-tissue culture plates. Approximately 3000 beads were added to 
each well with the cells, and the plates were incubated at 37°C for varying lengths of 
time (1-3 hours). Afterwards, the wells were washed with media (DMEM) several times 
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and viewed using fluorescent microscopy. The LR21 and 10V4 cells seemed to work the 
best compared to the MDA-MB-231 cell line. As seen in Figure 2.11, the cells attached 
to the positive control beads (peptides 1 and 3) and not to the negative controls beads 
containing scrambled versions of peptides 1 and 3 or the knockout cells. Unfortunately, 
the cells did not bind to every positive bead and the ones that showed binding were not 
completely coated with cells as typically seen with integrin expressing cells. Also, it was 
at times difficult to judge if there was a real interaction occurring because the cells tend 
to clump together and in some cases may have been floating on top of the bead instead 
of bound to it. 
                                                                                                                                                                                                                                                                  scra                                                                                                                                                                        
                                
Figure 2.11 Images taken of the interactions between cell lines (green) interacting with 
positive and negative control beads (top images: blue; bottom images: grey). A. 
Magnified image of 10V4 cells binding to positive bead. B. Image of positive beads 
containing peptide 3 interaction with 10V4 cells. C. Image of beads containing a 
scrambled sequence (negative control) showing very little to no interaction with the 10V4 
cells. D. Image of positive beads showing little to no interaction with the knockout cells. 
E. Image of positive beads containing peptide 1 interaction with LR21 cells    
 
Since the results were not consistent for every positive bead and were not able to 
accurately be quantified, the on-bead cell screening assay was abandoned. The method 
itself has its own limitations as well, especially for an OBOC library. In an OBOC library, 
A 
D 
B 
E 
C 
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the collection of hits by manual isolation of individual beads among millions under a 
microscope is labour intensive and time consuming. Overall, it is difficult to accurately 
assess the interaction of cells on a bead and manually separate the hits. 
 Alternatively, a “beads on a bead” screening approach has been developed 
which separates beads based on both magnetic and fluorescence sorting. This method 
is advantageous because it allows for magnetic bulk separation and afterwards 
fluorescence sorting. Furthermore, it allows for multiple proteins displayed on a 
fluorosphere.  First, the target protein is biotinylated and is adsorbed to 2 µm streptavidin 
coated magnetic/fluorescent screening beads (Figure 2.12).  
                                    
Figure 2.12 The biotinylated protein is adsorbed to steptavidin coated magnetic and 
fluorescent screening beads 
 
Upon mixing of the screening beads with the peptide library beads, they should 
associate with one another in an affinity-dependent manner. To validate the method, 
proof-of-principle experiments were previously performed by Cho et al. exploiting the 
binding of RGD containing peptides to αvβ3 integrin. Afterwards, the screening process 
was used to identify several high affinity 8-mer peptides for αvβ3 integrin from an OBOC 
library.102 The accurate and affordable strategy led us to adopt the method to screen the 
synthesized peptide analogues from the tip workstation to identify high affinity peptides 
with improved in vivo stabilities. The disadvantage in this method is that the native 
conformation of protein expressed at the cell surface can be very different compared to 
purified protein.  
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Due to the difficulty in producing pure RHAMM protein by recombinant methods, 
it was decided that a smaller section of RHAMM (7 kDa) containing the HA-binding 
domain, could be synthesized using solid-phase peptide synthesis. The 62 amino acid 
carboxy terminus of RHAMM containing the HA binding region was synthesized on the 
automated microwave synthesizer. This allows for the direct biotinylation of the N-
terminal amine as part of the synthesis on-resin. The method avoids the use of kits and 
lengthy purification procedures to remove excess biotin. In addition, as biotin is only 
coupled to the N-terminus, it does not interfere with the multiple lysines in the sequence 
to interrupt any binding within the HA binding region. A linker was added in order to 
increase the solubility of biotin. The synthesized peptide containing biotin was HPLC 
purified and characterized (Table 2.11). 
 
Table 2.11 Characterization of purified RHAMM 
Sequence Calculated Observed Purity 
[M+9H]
9+
 
Biotin-AEEA-RDSYAQLLGHQNLKQKIKHVVKLKDENSQLK 
SEVSKLRSQLVKRKQNELRLQGELDKALGIR-NH2 
846.1069 
(average) 
846.0906 >95% 
 
Longer peptide sequences are difficult to synthesize and purify because of the 
accumulation of side reactions and unwanted by-products. More recently, microwave 
irradiation has emerged as a method to improve the efficiency of solid phase peptide 
synthesis. The heating capability allows for the reduction of inter- and intra-molecular 
derived aggregation and secondary structure formation (β-sheets) which results in 
greater product purity/yield as well as faster reaction times.103 7 kDa RHAMM was 
synthesized on the microwave synthesizer in four separate syntheses, performing micro-
cleaves after each synthesis in order to check the purity and determine problem 
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sections. Afterwards, the hydrophilic linker and biotin were added manually and the 
peptide was purified on the HPLC. The yield was sacrificed to obtain a high purity 
(>95%) product. To confirm that this shorter length of RHAMM is still capable of binding 
to HA, an ELISA was performed using an ECHELON kit containing HA-coated plates 
(Figure 2.13). Varying concentrations of biotinylated RHAMM were added to the plates 
and the binding was detected with streptavidin-AP. The results demonstrate that this 
shorter length RHAMM is capable of binding HA and is suitable for determining the 
affinity and potential of the 95 peptide analogues. 
 
 
Figure 2.13 ELISA of HA-coated plates with varying concentrations of biotinylated 
RHAMM 
 
 2.4.6 Addition of RHAMM to Magnetic/Fluorescent Beads  
 Before RHAMM was adsorbed to the magnetic and fluorescent streptavidin 
beads, the beads were washed with PBS to remove sodium azide. Washings were done 
holding a strong neodymium magnet to the side of the vial for several minutes while 
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pipetting the liquid out. The beads were then incubated with biotinylated RHAMM for 1.5 
hours at room temperature. Biotin was then added into the solution and was incubated 
for an additional 30 minutes at room temperature to block any remaining streptavidin 
sites. To develop a procedure for screening the peptide analogues, first the control 
peptides were tested. The four controls (~0.5 mg) were incubated with the prepared 
RHAMM-coated magnetic/fluorescent beads (5 μL) (1.5 hr, 37°C). After the incubation 
period, the tentagel beads were washed five times to remove the unbound magnetic 
beads. To determine the limits for negative and positive hits, they were analyzed in a 
plate reader (ex 560 nm, em 590 nm) before incubation and after washing. This 
procedure was performed in triplicate to ensure its reliability. The fluorescent values 
were calculated as a ratio of total magnetic beads:bound beads left after washing and 
the values were normalized. The averages were calculated from normalized values and 
were set as the limits for positive and negative hits (Table 2.12).  
 
Table 2.12 Synthesized controls for screening of analogues and their average 
normalized values from the fluorescent plate reader (560 nm, 590 nm) 
 
# Peptide Average Normalized Value 
3 FTEAESNMNDLV (positive) 0.78 
Scrambled 3 SVNLEFMANEDT (scrambled-negative) 0.23 
1 VEGEGEEEGEEY (positive) 0.51 
Scrambled 1 GYGEEEEVEEGE (scrambled-negative) 0.38 
 
The same procedure was carried out for the 95 synthesized analogues. Similarly, the 
ratio of total magnetic beads:bound beads was calculated for each peptide and the 
values were normalized and compared to the averages found for the controls. The 
screen resulted in several positive hits for both peptides (Table 2.13), however more 
were found for peptide 1 due to the lower limit for a positive hit. 
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Table 2.13 Sequences for positive hits with improved values over their respective 
positive control 
 
Original Sequence FTEAESNMNDLV VEGEGEEEGEEY 
Sequences of positive hits FTEaESNMNDLV VEGEGEEeGEEY 
F(β-HThr)EAESNMNDLV VEGEAEEEGEEY 
FTEAESNMN(CA)LV VEGEGDEEGEEY 
 VEGEGEEEGEAY 
 VEGEGEEEGEENal 
 VEG(CA)GEEEGEEY  
    
  
Figure 2.14 Images of positive hits resulting from “beads on a bead” screen. Small red 
magnetic beads coating a tentagel bead containing a positive sequence  
 
Some of the positive hits were viewed under a fluorescent microscope and images were 
taken (Figure 2.14). The results of the two replacements of glycine with alanine in 
peptide 1 are confirmed by the alanine scans. For example, there was a significant 
increase in the fluorescence for the replacement of G11 with A using the new screening 
methodology and in the alanine scan, there was a noticeable improvement in 
fluorescence. Also, it seemed that peptide 1 benefited through the replacement of Tyr 
with the bulky Nal, possibly because of its hydrophobic nature. In peptide 3, it seems 
that cysteic acid, a more acidic amino acid, is able to replace aspartic acid with 
significantly improved affinity, but not glutamic acid as the affinity decreased greatly 
when the two glutamic acids were replaced. Another large improvement resulted from 
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the replacement of Thr with β-homo-Thr which contains an extra carbon added into the 
peptide backbone. Beta-amino acids have the advantage of resembling the activity-
related structural features of the natural peptide while offering well defined secondary 
structure due to their extended backbone.104 There were also several peptides that were 
on par with the controls and may be advantageous due to their possession of unnatural 
amino acids (Table 2.14). 
 
Table 2.14 Sequences of peptides containing unnatural amino acids with comparable 
values to their respective positive control 
 
Original Sequence FTEAESNMNDLV VEGEGEEEGEEY 
Sequences of positive hits FTeAESNMNDLV VEGEGeEEGEEY 
FTE(Aib)ESNMNDLV VEGEGEeEGEEY 
FTEAESN(Thi)NDLV VEGEGEEEGEeY 
FTEAE(Ser-OMe)NMNDLV VEGEGEEEGEE(Phe-4-F) 
 VEGEGE(CA)EGEEY 
 VEGEGDEEG(CA)EY 
 
For each peptide there was an improved affinity seen when the specific position of one 
amino acid (peptide 3: 4, peptide 1: 8) was changed to its D-amino acid counterpart. 
There were also comparable affinities with D-amino acid replacements in other positions. 
It is possible that the combination of two or more D-amino acids may increase the overall 
affinity. The glutamic acids present in peptide 1 also seem to be more susceptible to 
other acidic residues (cysteic acid) in comparison to peptide 3 and may potentially 
benefit from the combination of multiple cysteic acids. Peptide 3 resulted in comparable 
affinity when the methionine cyclized mimic, Thi, was used as well as when the alcohol 
functional group of serine was replaced with a methoxy group. Finally, the tyrosine 
residue in peptide 1 appears as if it can be modified with comparable affinity by similar 
residues. There were also obvious important amino acids in peptide 3 whose values 
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significantly decreased when replaced with other amino acids containing different 
functional groups. Such amino acids include N7, M, L and V. Overall, this screening 
methodology was successful in identifying initial positive hits with potential improved 
affinity for RHAMM as well as peptides containing unnatural amino acids with 
comparable or greater affinity for RHAMM than the controls 1 and 3.  
 
2.5 Conclusions 
 Synthetic peptides representing the carboxy terminal tail of various tubulin 
isoforms were discovered to mimic hyaluronan. Through bioinformatics and SPR, the 
lead candidate peptides were found to target RHAMM with high affinity and specificity. 
The main goal of this project was to develop the candidate peptides into imaging agents 
and perform in vivo studies. The three peptides were synthesized with a linker and 
DOTA chelator onto the N-terminus. Afterwards, cold 69/71Ga and radioactive 68Ga 
studies were performed for the peptides. Specifically, two of the peptides showed 
promise and their labelling conditions were optimized to produce good radiochemical 
yields, and high specific activities and radiopurities. In vivo cell studies were performed 
for the two peptides. The results showed that these peptides are not able to target 
RHAMM effectively in vivo. The second goal of the project was to develop analogues of 
the peptides incorporating unnatural amino acids to improve in vivo stability and 
potentially improve affinity for RHAMM. First, the critical amino acids were determined by 
alanine scans and peptide 2 was found not to have any important amino acids, so was 
no longer used for subsequent studies. For peptides 1 and 3, unnatural bioisosteres 
were used for the replacement of critical amino acids and amino acids possessing 
various functional groups were tried for the replacement of noncritical amino acids. A 
total of 99 peptides were synthesized in small amounts on the tip workstation. The 
 49 
 
screening of these peptides consisted of incubating them with RHAMM-coated 
magnetic/fluorescent beads and analysis using a plate reader. The initial screen resulted 
in three novel analogues of peptide 3 and six new analogues of peptide 1 with potential 
improved affinities for RHAMM. In addition, a total of 10 peptides were discovered with 
comparable affinities for RHAMM, but containing unnatural amino acids. The initial 
design of the analogues utilized a rational approach only replacing one amino acid at a 
time to determine specific replacements with improved affinity. Future optimizations may 
include the combination of several replacements of amino acids that showed improved 
affinity for RHAMM. This offers the possibility of increased stability in vivo while 
maintaining the same or better affinity for RHAMM as previously found. As mentioned, 
this was an initial screen of analogues and the positive hits will need to be synthesized 
and validated with further studies. Finally, 7 kDa RHAMM was able to be synthesized 
using SPPS and was shown to maintain its affinity for hyaluronan through an ELISA 
assay as well as the analogue screen which produced novel sequences. The discovery 
of the relevancy of the truncated version of RHAMM is extremely valuable for groups 
working with this protein as it expedites the synthesis and purification procedures, yet 
results in very high purity products. 
 
2.6 Experimental Procedures 
2.6.1 General Experimental procedure for peptides 
All standard Fmoc protected amino acids and coupling agents, except HATU (Nova 
Biochem), were obtained from Peptides International. Unnatural amino acids used in the 
library were obtained from Chem-Impex, Matrix Scientific and Sigma Aldrich. Fmoc-Rink 
amide MBHA resin (4-(2’,4’-dimethoxyphenyl-(9-fluorenylmethoxycarbonyl)-
aminomethyl)-phenoxy-acetamidonorleucyl-4-methyl benzhydrylamine resin) was 
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obtained from Nova Biochem. Tentagel S NH2 resin was obtained from Chem-Impex. 
RP-C18 Sep-Pak© cartridges were obtained from Waters. 68Ge-68Ga generator was 
obtained from Eckert and Ziegler. 
2.6.2 Peptide Syntheses 
Fmoc-based solid-phase peptide synthesis was carried out manually or automatically 
with 0.05 or 0.1 mmol of 0.52 mmol/g Fmoc-Rink amide MBHA resin and a 3-fold excess 
of the protected amino acids. Fmoc removal, carried out with 20% piperidine in N,N-
dimethylformamide (DMF) over two cycles (5 and 15 min), rinsing with DMF and 
dichloromethane (DCM) twice after each cycle and the Kaiser test is performed to 
confirm the presence of free primary amino groups.95 Afterwards, amino acid activation 
took place with 3 eq HCTU and 6 eq N,N diisopropylethylamine (DIPEA) (5 min) and 
subsequent coupling over 30 and 60 min cycles, rinsing three times with DMF and DCM 
after each cycle. Coupling of Fmoc-protected aminohexanoic acid (Ahx) and 2-[2-(2-
aminoethoxy)ethoxy]acetic acid (AEEA) followed the same methodology used in amino 
acid coupling.  FITC coupling was carried out using FITC fluorescent dye (4 eq.) and 
DIPEA (2 eq.) in DMF for four hours. Biotin was coupled using NHS-biotin (3 eq) and 
DIPEA (6 eq) in DMF overnight. Full deprotection of synthesized peptides was 
accomplished using a solution of 95% TFA (v/v), 2.5% H2O (v/v), 2.5% triisopropylsilane 
(v/v) over 5 hours. The cleaved peptides were then precipitated using tert-butyl methyl 
ether (TBME) and centrifuged at 2200 rpm for 15 min. After decanting, the peptide pellet 
was rinsed with TBME, vortexed and centrifuged again. Following the removal of the 
supernatant, the peptide pellets were dissolved in water, frozen at 78°C and lyophilized. 
In order to monitor reaction progress and peptide purity via HPLC, small samples of the 
resin were cleaved using the same procedure as outlined above for full deprotection. 
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2.6.3 Purification by RP-HPLC / ESI-MS 
Peptides were analyzed using a reverse-phase analytical HPLC column (SunfireTM RP-
C18 column 4.6 x 150 mm, 5 μm). This system was equipped with a Waters 600 136 
controller, Waters Prep degasser, and Waters MassLynx software (version 4.1). 
Employed mobile phases were 0.1% TFA in water (eluent A) and 0.1% TFA in CH3CN 
(eluent B). The linear gradient used was 10-40% of B with a flow rate of 1.5 mL min-1 
over 10 min. The column eluate was monitored using a Waters 2998 Photodiode array 
detector set at 220, 254 and 400 nm. Peptides were purified using a reverse-phase 
preparative HPLC column (SunfireTM Prep RP-C18 OBDTM column 19 x 150 mm, 5 μm) 
on the same system mentioned above. The detection method along with eluents and 
gradients were the same as those stated above, with the exception of the flow rate being 
set at 20 mL min-1. The collected fraction was then lyophilized to a solid and 
subsequently analyzed by ESI-MS (electrospray ionization mass spectrometry) (Waters 
Micromass Quattro MicroTM API). Purity of final products was determined by analytical 
RP-HPLC (220 nm). 
2.6.4 69/71Ga Labeling 
In a typical reaction, 5 mg of the DOTA-peptide was dissolved in 0.1 M pH 4 NaOAc 
/HOAc buffer. Chelation was carried out using a three-fold excess of anhydrous GaCl3 at 
75°C over 30 minutes. Resulting mixture was cooled prior to purification by a plus C18 
RP Sep-Pak© (conditioned with 6 mL of ethanol and 25 mL of water). After passing the 
reaction mixture through the Sep-Pak©, 10 mL of water was used as eluent in order to 
wash out residual unreacted GaCl3. A 6 mL aliquot of EtOH was used to wash out the 
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labelled product. The resulting solution was then dried on a rotary evaporator, mixed 
with 5 mL of H2O, frozen at -78°C and subsequently lyophilized overnight. 
2.6.5  68Ga Radiolabelling 
To a clean glass microwave vessel was added 200 μL of a DOTA-peptide solution (0.1 
mg/mL in pH 3.5 HEPES buffer). This aliquot was dissolved in 800 μL of the buffer (10 
fold dilution to obtain final solution with μM concentration), to which ~300 MBq 68Ga was 
added, freshly eluted from the Ge-68/Ga-68 generator using 3 mL of 0.1 M HCl. 
Purification and isolation of 68Ga was achieved using a Phenomenix Strata-X-C 33u 
polymeric strong cation exchange column with 0.05 N HCl in acetone as the eluent. The 
reaction mixture was then heated in the reactor of the automated synthesis module at 
80°C for 30 minutes (or manually heated in an oil bath at 90°C for 10 minutes), prior to 
Sep-Pak© purification using a light RP-C18 SPE Sep-Pak cartridge© (conditioned with 5 
mL of ethanol and 5 mL of water). After passing the reaction mixture through the Sep-
Pak©, 3 mL of water was used as eluent in order to wash out residual unreacted 68Ga. A 
2 mL aliquot of EtOH was used to wash out the radiolabeled product. After evaporation 
on the V-10 1.6 Biotage® vortex and vacuum evaporation system, the reaction progress 
and product purity was analyzed using analytical RP-HPLC (SunfireTM RP-C18 column 
4.6 x 150 mm, 5 μm) coupled to a gamma detector, prior to further use in animal studies. 
HPLC system employed a Waters 1525 Binary HPLC pump, Waters 2487 dual 
absorbance detector, Waters In-Line degasser and Breeze software (version 3.30). 
 
2.6.6 In Vivo Study 
In vivo imaging studies were conducted in Nod/Scid with tumours either in the fourth 
mammary gland or flank. The injection of 7c or 9c (3.0-6.0 MBq) was done in the tail 
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vein of the mice. Mice were euthanized 2 hours post injection. The organs and tumour 
were then removed and assayed. Biodistribution was calculated as % injected dose/g. 
 
2.6.7 ELISA Binding Assay for RHAMM 
A 96-well plate coated with HA (Echelon) was incubated with varying concentrations of 
biotinylated 7 kDa RHAMM (0-10.5 μM) overnight at 4°C. The next day it was washed 
three times with 200 μL wash concentrate (K-1205). Streptavidin-alkaline phosphatase 
(100μL) was added and the plate was incubated at 37°C for 30 min. Wells were washed 
three times with wash concentrate. Next, 100 μL of p-nitrophenyl phosphate (PNPP) (1 
tablet in 11 mL substrate buffer) was added in the dark and absorbance at 405 nm was 
recorded for each well. 
 
2.6.8 Generation of RHAMM-Coated Magnetic/Fluorescent Screening Beads 
Two-micron streptavidin-coated fluorescent (pink) magnetic beads (Spherotech) were 
washed three times with phosphate buffered saline (PBS) and secured using a strong 
neodymium magnet to remove sodium azide. 50 μg of the magnetic beads were 
incubated with 5 μg of biotinylated RHAMM for 1.5 hours at 25°C. 20 μg of biotin was 
added into the solution and incubated for an additional 30 mins at 25°C to block any 
remaining streptavidin sites. The RHAMM-coated magnetic/fluorescent beads were 
washed three times in PBS and secured using a magnet. 
2.6.9 Library Screen 
The synthesized peptides on tentagel beads were washed twice with ethanol, and three 
times with binding buffer (25 mM Tris-HCl, 145 mM NaCl, 5 mM KCl, 1 mM 
MgCl2, 0.02 % Triton-X 100, pH 7.4). First, the positive and negative control peptides 
were screened against the beads. The controls (~0.5 mg) were suspended in 100 μl of 
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binding buffer. 5 μl of RHAMM-coated screening beads were added into each tube 
containing the tentagel beads. This procedure was performed in triplicate. The initial 
fluorescence values were measured in a plate reader (Synergy H4: ex 560 nm em 590 
nm) before incubation to determine the total number of magnetic beads. They were 
incubated for 1.5 hours at 37°C with constant shaking. After incubation the beads were 
washed five times with binding buffer. They were then transferred into a 96-well plate 
and analyzed on a plate reader. The results of the read determined the limits for a 
negative and positive hit by calculating the ratio of total magnetic beads:bound magnetic 
beads and the values were normalized. The same procedure was performed on the 
synthesized analogues and the normalized values were compared to the control values.  
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Chapter 3: Truncated GLP-1 Imaging Agents for 
Pancreatic Beta Cell Imaging 
3.1    Introduction 
Diabetes mellitus is a metabolic disorder that affects millions of people. It has 
been increasing worldwide and is expected to reach 438 million by 2030.105 The striking 
increase in the prevalence of diabetes leads to a significant socioeconomic problem.  It 
is characterized by chronic hyperglycemia due to defective insulin action, secretion or 
both.106 Several processes are involved in the development of diabetes including the 
destruction of insulin-producing pancreatic beta cells, as well as enhanced resistance to 
insulin action. The lack of insulin results in abnormalities typically observed in 
carbohydrate, fat and protein metabolism.106 Consequently, research into diabetes 
should aim at the preservation and expansion of pancreatic beta cell mass. Molecular 
imaging techniques can aid in monitoring of the onset of diabetes and its progression 
into type 2, which may allow for earlier detection and treatment.  
Glucagon-like peptide-1 (GLP-1) is a peptide hormone produced by intestinal L-
cells in response to nutrient ingestion. It is one of three products formed from the 
processing reactions of the larger precursor proglucagon. Other peptide fragments 
include GLP-2 and glicentin.107 GLP-1 exists predominantly as a 30 amino acid, C-
terminally amidated peptide, GLP-1(7-36). It has been shown to reduce glucagon 
secretion (whose role is to raise blood glucose levels) and strongly increase insulin 
secretion.108 GLP-1 exerts its effects by binding to the GLP-1 receptor (GLP-1R).  Due to 
the structure of the receptor, it is classified in the family B subclass of the G protein-
coupled receptor (GPCR) superfamily. The structural characteristics of the receptors in 
this family include a long extracellular N-terminal domain, disulfide bridged cysteine 
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residues in the extracellular domains, and several glycosylation sites.109 Structure-
function studies of the GLP-1R have shown that the helical region of GLP-1 interacts 
with the extracellular N-terminal domain of the GLP-1R, while the N-terminal 8 amino 
acids of GLP-1 interact with residues in the extracellular regions and transmembrane 
helices of the receptor.110 The receptor responds to at least four distinct endogenous 
GLP-1 variants. These include a full-length peptide GLP-1(1-37) and a truncated form 
GLP-1(7-37), as well as the amidated counterparts GLP-1(1-36)-NH2 and GLP-1(7-36)-
NH2. The receptor has also been found to respond to the related peptide oxyntomodulin 
and exogenous mimetic peptides such as exendin-4. Oxyntomodulin is a 37-amino acid 
peptide found in the colon and binds to both GLP-1R and glucagon receptor, however, 
its mechanism of action is not known.111 Exendin-4 is a 39-amino acid hormone found in 
the saliva of the Gila monster that was first isolated by Dr. John Eng in 1992.112 It is a 
very potent and stable GLP-1R agonist with a plasma half-life of 26 min. GLP-1R 
couples primarily to Gαs, and upon the binding of GLP-1 to its receptor, it activates 
adenylate cyclase (AC), cAMP production, and an increase in cytosolic calcium that 
ultimately promotes insulin secretion (Figure 3.1).113                                                                           
       
Figure 3.1 The role of GLP-1 in insulin secretion                                                     
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As GLP-1 binds to its receptor on the pancreatic beta cell, it triggers the release 
of insulin in a glucose-dependent manner which is known as the “incretin effect”. When 
administered to type 2 diabetic subjects, GLP-1 normalizes blood glucose levels, 
increases circulating insulin, and diminishes glucagon secretion. GLP-1 receptor 
signaling events also lead to the stimulation of beta cell proliferation, survival and 
differentiation.114 Thus, GLP-1 may a valuable candidate in the treatment of type 2 
diabetes.  
The major disadvantage to GLP-1 as a therapeutic agent is its short half-life of 2 
min in vivo. This is due to the protease, dipeptidyl peptidase-IV (DPP-IV) cleaving the 
His-Ala dipeptide from the N-terminus.114 Through key amino acid substitutions and 
modifications, discoveries have been made to improve the biological half-life of GLP-1. 
Examples include the substitution of Ala for D-Ala, Gly or Aib at position eight.115 Alanine 
scanning experiments have shown that amino acids in positions 7, 10, 12, 13 and 15 
were directly involved in receptor binding and activation, whereas those in positions 
28 and 29 maintained the secondary structure of the peptide necessary for receptor 
recognition.116 It can be concluded from the scan that the N-terminal region is most 
important for binding to the receptor. Work done by Mapelli and colleagues discovered a 
minimal sequence GLP-1 analogue that is a potent agonist for GLP-1R.117 
The N-terminal 9-mer sequence of GLP-1 was chosen as the truncated version 
of the peptide because five of the amino acids critical for binding were located in that 
region. Mapelli and colleagues found that a slightly modified 9-mer peptide sequence of 
GLP-1 with the addition of two biphenyl alanine residues (BIP 1 & 2) is a nanomolar 
active full agonist of the GLP-1 receptor (Figure 3.2).117  
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                                     23                                                                   24 
Figure 3.2 Structures of BIP 1 (23) and BIP 2 (24)117 
With a 10-fold increase in activity over the original sequence of GLP-1, the modified 
truncated version 26 shows great promise as a therapeutic agent (Table 3.1).  
Table 3.1 Comparison of sequences between GLP-1(7-17) and the modified version 
developed by Mapelli et al.117 
 
Compd Name Sequence 
25 GLP-1(7-17)-amide H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-NH2 
26 [Aib
8
, α-Me-Phe
12
, BIP 2
16
, BIP 1
17
]   
GLP-1(7-17)-amide 
H-His-Aib-Glu-Gly-Thr-α-MePhe-Thr-Ser-Asp-24-23-NH2 
 
We now propose that by creating a radiolabelled analogue of 26 ([Aib8, α-Me-Phe12, BIP 
216, BIP 117] GLP-1(7-17)-amide), an imaging probe will be developed for studying 
pancreatic beta cell mass in vivo. This would generate a targeted PET imaging agent for 
GLP-1R through binding at an allosteric site, which in turn may potentially offer greater 
receptor selectivity due to higher sequence divergence in comparison to the conserved 
orthosteric domain. 
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3.2 Previous Research 
 In an attempt to image pancreatic islets, our group developed GLP-1(7-36) into 
an imaging agent and labelled with 68Ga as well as 111In. First, an in vitro imaging study 
was carried out using 111In and the clonal insulin-producing beta cell line INS-1 832/13, 
which expresses GLP-1R. It demonstrated specific binding of the GLP-1 analogue, as it 
was displaced by exendin-4.118 Next, in vivo studies were performed, and preliminary 
data indicated specific uptake of the probe in the pancreas of C57BL/6 mice. 
Unfortunately, the probe was strongly retained in the kidneys and prevented the 
visualization of the pancreas in PET and SPECT imaging.119 Reports have indicated a 
reason for the high kidney uptake to be the presence of multiple positively charged 
amino acids in the peptide chain.120, 121  
 One possible solution to this is to use a truncated version of GLP-1(7-36) and 
greatly reduce the number of charged residues. Modifications have been discovered in 
order to improve the biological half-life of GLP-1 through key amino acid substitutions. 
Ala-8 is very susceptible to DPP-IV cleavage, but replacing it with an unnatural amino 
acid, α-aminoisobutyric acid (Aib), resulted in a more stable analogue while retaining the 
same potency as native GLP-1. Mapelli and colleagues took a minimal sequence 
approach that kept the first 9 N-terminal amino acids of GLP-1(7-36).117 The group 
modified the sequence and these shortened peptides were assessed in vitro for 
functional activity. The initial scan resulted in an 11 mer peptide containing two 
biphenylalanine (BIP) residues at the C-terminus. Both BIP residues were found to be 
critical for activity. The optimized BIP residues contained 2’-ethyl-4’methoxy-BIP (BIP 2) 
in position 10 and 2’-methyl-BIP (BIP 1) in position 11. A final substitution resulted in a 
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decrease from EC50 = 7 nM to 0.28 nM by substituting Phe with α-Me-Phe in position 6 
(26).117 
3.3 Project Goal 
 The aim of the research is to develop a novel imaging agent based on a DOTA 
chelated 26 probe that will target GLP-1 receptor. The first step involves the synthesis of 
the two small molecules, 23 and 24, and afterwards incorporating them into peptides. 
Next, the EC50 and IC50 of 26 and its DOTA analogues must be determined, at which 
point they will be developed into imaging agents by incorporating the radionuclide 68Ga. 
This will allow for non-invasive PET imaging which may provide a method of studying 
pancreatic beta cell mass in vivo and ultimately, the onset and progression of diabetes. 
3.4 Results and Discussion 
3.4.1 Small Molecule Synthesis 
 The Fmoc-protected amino acids of BIP 1 and BIP 2 are not commercially 
available, resulting in the first step of this project being the synthesis of both following a 
literature procedure.117 The two molecules are synthesized following similar synthetic 
routes, and only differ in the boronic acid used for the Suzuki coupling. The synthesis 
begins with Boc-L-tyrosine methyl ester which is mesylated to produce 27, requiring no 
further purification (Scheme 3.1). This compound is the starting material used in the 
Suzuki coupling for both BIP compounds. For BIP 1, the Suzuki coupling between the 
triflate 27 with o-tolylboronic acid resulted in the biphenyl product 28 in reasonable yields 
after flash column chromatography. The reaction needed at least 1.4 equivalents of 
boronic acid in order to fully react with the starting material. With less, purification 
became difficult due to the similar Rf values of the starting material and product. The 
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procedure for the methyl ester deprotection and the Boc deprotection differed from the 
literature, but both went smoothly with very good yields (29 and 30, respectively). The 
final step was the Fmoc protection of the amine. The purification was difficult because 
there was excess Fmoc-OSu after the reaction, which has a similar Rf to the product. In 
an attempt to eliminate excess Fmoc-OSu for an easier purification, Fmoc-Cl was 
instead used. The reaction was done in dioxane/water and NaHCO3 was used as the 
base with 1.5 eq of Fmoc-Cl. No column was needed as the product precipitated out 
once dioxane was removed. However, this approach resulted in low yields (<30%) thus 
Fmoc-OSu was used when repeating this reaction. For this reaction to be successful 
there needs to be a balance between the amount of remaining starting material and 
excess Fmoc-OSu after the reaction is complete. Using the conditions shown in scheme 
3.1, BIP 1, 23, was produced in a reasonable yield as an off-white solid. 
 
Scheme 3.1 The synthetic route for BIP 1117 
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For the synthesis of BIP 2, the boronic acid was not commercially available and needed 
to be prepared following a literature method (Scheme 3.2). The first step in the synthesis 
of (2-ethyl-4-methoxy) phenylboronic acid was reacting 2-ethyl phenol with MeI and 
base. After refluxing overnight, the reaction was complete but after several attempts with 
very poor yields, it was suspected that the product 31 is volatile and was being lost on 
the vacuum pump. The solvent was only removed on the rotary evaporator and yields 
were calculated based on the solvent remaining that can be seen in the 1H NMR. 
Therefore, an accurate yield can still be obtained by this method and indirectly 
calculating the yield instead of evaporating off the solvent completely by the vacuum 
pump and ultimately losing much of the product. The bromination was performed in the 
dark to ensure it was not a radical reaction initiated by light. The reaction was clean with 
no need for flash chromatography. The product 32 was dissolved in hexanes and the by-
product, succinimide, was insoluble and was filtered off. The final step uses n-BuLi and 
tri-n-butylborate to produce crude boronic acid. After fully drying the product on vacuum, 
the solid is stirred in hexanes and the white crystals are filtered off as the pure boronic 
acid 33. The yield was poor due to much of the boronic acid remaining in the mother 
liquor and not precipitating. The mother liquor needed to be concentrated several times 
to produce an adequate yield. 
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Scheme 3.2 The synthesis of (2-ethyl-4-methoxy) phenylboronic acid117 
 
The synthesis of the Fmoc-protected BIP 2 was similar to the synthesis of BIP 1. 
The Suzuki coupling was first attempted using the same conditions as BIP 1, but 
ultimately needed a slightly different procedure in order to go to completion. In reference 
to the literature, the reaction used four different solvents as well as a higher temperature 
of 100°C. The triflate 27 coupled with (2-ethyl-4-methoxy) phenylboronic acid 33 resulted 
in the biphenyl product 34 in reasonable yields after flash column chromatography. 
Similarly, the boronic acid 33 needed to be at least 1.4 equivalents in order to fully react 
with the starting material, easing purification. The procedure for the methyl ester 
deprotection and the Boc deprotection remained the same as with BIP 1 with similar 
yields (35 and 36, respectively). The final step was the Fmoc protection of the amine, 
where the purification was difficult because of excess Fmoc-OSu after the reaction, 
which has a similar Rf to the product. Both DIPEA and NaHCO3 were tried as bases and 
Fmoc-Cl was tried instead of Fmoc-OSu, however the conditions giving the best results 
are shown in scheme 3.3. BIP 2 24 was produced in a reasonable yield as an off-white 
solid. 
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Scheme 3.3 The synthetic route for BIP 2117 
 
With the two BIP compounds successfully synthesized and fully characterized, the next 
step was to include the compounds into the reported 11-mer peptide (26): [Aib8, α-Me-
Phe12, BIP 216, BIP 117] GLP-1(7-17)-amide.  
 
3.4.2 Peptide Synthesis 
The novelty of this project is the development of 26 into an imaging agent. For this to be 
possible, the peptide must first be synthesized with a lysine on the C-terminus onto 
which DOTA will be coupled (Figure 3.3). One peptide (37) is directly coupled to the 
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chelator, while the other (38) contains a mini PEG linker, AEEA (2-[2-(2-
aminoethoxy)ethoxy]acetic acid), to add distance between the peptide and the chelator. 
                                                              
     
Figure 3.3 Structures of [Aib8, α-Me-Phe12, BIP 216, BIP 117, Lys18(DOTA)] GLP-1(7-18)-
amide, 37, and [Aib8, α-Me-Phe12, BIP 216, BIP 117, AEEA18, Lys19(DOTA)] GLP-1(7-19)-
amide, 38 
 
The syntheses were done manually and the Kaiser test was used to ensure proper 
coupling and deprotection took place, particularly for the valuable BIP 1 and BIP 2. 
Several attempts were performed, varying the coupling times for several of the unnatural 
amino acids. Particularly, Thr11 proved to be difficult to couple onto α-Me-Phe and 
needed a more reactive coupling agent, HATU, as well as a longer time period. Once the 
difficult steps were worked out, the three peptides were synthesized and characterized 
(Table 3.2).  
 
 
 
 
Peptide= H-His-Aib-Glu-Gly-Thr-α-MePhe-Thr-Ser-Asp-BIP2-BIP1 
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Table 3.2 Characterization of peptides by ESI-MS and UHPLC 
# Peptide Calculated Found Purity 
(%) 
[M+2H]
2+
 
26 [Aib
8
, α-Me-Phe
12
, BIP 2
16
, BIP 1
17
] GLP-1(7-17)-amide 755.3566 755.3455 >95 
37 [Aib
8
, α-Me-Phe
12
, BIP 2
16
, BIP 1
17
, Lys
18
(DOTA)] GLP-
1(7-18)-amide 
1012.9957 
[M+3H]
3+ 
= 
675.6664 
1013.0044 
[M+3H]
3+ 
= 
675.6643 
95 
38 [Aib
8
, α-Me-Phe
12
, BIP 2
16
, BIP 1
17
, AEEA
18
, 
Lys
19
(DOTA)] GLP-1(7-19)-amide 
1085.5326 
[M+3H]
3+ 
= 
724.0244 
1085.5471 
[M+3H]
3+ 
= 
724.0230 
94 
37b [Aib
8
, α-Me-Phe
12
, BIP 2
16
, BIP 1
17
, Lys
18
(
69/71
Ga-DOTA)] 
GLP-1(7-18)-amide 
1046.4467 1046.4424 94 
38b [Aib
8
, α-Me-Phe
12
, BIP 2
16
, BIP 1
17
, AEEA
18
, 
Lys
19
(
69/71
Ga-DOTA)] GLP-1(7-19)-amide 
1118.9836 1118.9816 94 
 
3.4.3 68Ga labeling 
In order to confirm that the coordination with gallium is possible in good yields and high 
specific activity, both naturally occurring 69/71Ga and radioactive 68Ga labelled analogues 
were synthesized for compounds 37 and 38. Table 3.2 shows the purities of the 
compounds along with their characterization by ESI-MS. As in previous studies, the 
peptides were coordinated with cold 69/71Ga in the presence of a sodium acetate buffer. 
After the reaction was complete, it was purified using a pre-conditioned Sep Pak C18 
plus and characterized using UHPLC-MS (ESI). The structures of each compound and 
their respective UHPLC trace are shown in Figure 3.4.  
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Figure 3.4 Peptide structures and UPLC traces for A. peptide 38b and B. peptide 37b 
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The compounds were radiolabelled with 68Ga using an Eckert and Ziegler 68Ge/68Ga 
generator connected to a series of synthesis modules. The optimized labelling conditions 
consisted of using 0.5 M HEPES buffer (pH 3.4) and a manual reaction using 20 µg of 
precursor and heating for 10 minutes at 90°C (Table 3.3).   
 
Table 3.3 Optimized labelling conditions for the two truncated GLP-1 analogues 
 [Aib
8
, α-Me-Phe
12
, BIP 2
16
, BIP 1
17
, 
Lys
18
(
69/71
Ga-DOTA)] GLP-1(7-18)-
amide 
[Aib
8
, α-Me-Phe
12
, BIP 2
16
, BIP 1
17
, 
AEEA
18
, Lys
19
(
69/71
Ga-DOTA)] GLP-
1(7-19)-amide
 
Compound number  
37c 
 
38c 
Precursor Amount 
(ug) 
 
20 
 
10 
 
20 
Specific Activity 
(GBq/µmol) 
 
>30 
 
>4 
 
>32 
Radiochemical yield 
(%) d.c. 
 
73 
 
4 
 
71 
Radiopurity (%)  
>99 
 
>99 
 
>99 
 
From the results, it is evident both compounds are able to be labelled with 68Ga in good 
yields and with high specific activities. The compounds were then tested in in vitro 
studies, to determine the IC50, EC50 and if they have the potential to be imaging agents 
for GLP-1R by incubating the radiolabelled compounds with cells that overexpress the 
GLP-1 receptor. 
 
3.4.4 In vitro studies 
The first cell-based assay was performed in order to determine the competitive binding 
affinity for GLP-1R of the control peptide 26 as well as the two candidate peptides, 37 
and 38 versus the GLP-1R competitive antagonist exendin-4(9-39). Receptor binding 
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was measured by the displacement of [125I]-exendin-4(9-39) with increasing 
concentrations of the 69/71Ga-coordinated truncated GLP-1 analogues. However, the 
peptides proved to show no affinity to the GLP-1R and could not compete with exendin-
4(9-39) > 1 μM. The next question posed was if the peptides are able to activate the 
GLP-1 receptor and stimulate the production of intracellular cAMP. As GLP-1 binds to its 
receptor on the beta cell, intracellular Gαs is activated, resulting in the stimulation of 
transmembrane adenylyl cyclases (tmACs) and an increase of cAMP levels. This in turn 
promotes glucose-dependent insulin secretion. This is the best studied pathway of GLP-
1R, so is the most common test for potential agonists. The peptides were able to 
increase cAMP concentrations in CHO/GLP-1R cells and show that they can act as 
GLP-1R agonists (Table 3.4). The peptides were not as potent as the control agonist, 
exendin-4, but were still able to act as strong agonists for the GLP-1R. Moreover, the 
addition of the chelator and 69/71Ga did not seem to have much of an influence on the 
stimulation of cAMP, still obtaining an EC50 value in the low nM range. 
 
Table 3.4 EC50 values for cold 
69/71Ga coordinated GLP-1 analogues and controls 
Compound EC50 (nM) 
Exendin-4 0.093
122
 
26 8.93 
37b 46 
38b 48 
 
Since the peptides are not able to displace exendin-4(9-39) in a competitive assay which 
is a potent antagonist of the GLP-1R, but are still able to promote cAMP production, it is 
thought the peptides are acting as allosteric agonists instead. Allosteric ligands bind at 
sites distinct from the orthosteric binding site recognized by the receptor’s endogenous 
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agonist.123 Allosteric agonists are capable of adjusting the binding of orthosteric ligands. 
It is possible for the allosteric modulator to act at the same receptor and be an enhancer 
of one orthosteric ligand, an inhibitor of another and have no effect on a third.124 The 
term ago-allosteric modulator has been coined for ligands that display allosteric agonism 
as well as the ability to modulate the binding of the orthosteric ligand (positively or 
negatively) instead of just ligands that display agonism or modulation.125 Within the past 
decade, interest has grown in targeting ligands to allosteric sites on GPCRs. In order to 
overcome the limitations of many orthosteric targeted ligands, allosteric ligands were 
sought to provide novel receptor selectivity. Few allosteric ligands of GLP-1R have been 
reported, so little is known about the allosteric modulation of GLP-1R. However, of the 
few compounds that have been reported, there is evidence of an allosteric pocket in the 
GLP-1 receptor. Some examples of allosteric small molecule modulators for GLP-1R 
include a substituted quinoxaline, referred to as “compound 2”,126 a pyridimine-based 
compound, BETP,127 and a substituted cyclobutane, Boc5.128  
 
Figure 3.5 Small molecule allosteric modulators of GLP-1R. A. “compound 2” B. BETP 
C. Boc5 
 
 The mechanism of activation and the location of the allosteric pocket of GLP-1R 
is unknown at this point. In the past, GPCRs have been viewed as monomeric, however, 
in recent years many studies have shown that GPCRs exist as dimers or high oligomers. 
Therefore, a “functional receptor” may be a homo- or sometimes even a hetero-dimeric 
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protein complex, most likely bound to a single hetero-trimeric G protein.125 It is possible 
that an allosteric activator may be acting via stimulation of receptor dimerization. In a 
dimeric system, an allosteric ligand can bind to the “other” receptor protomer within the 
dimer and thus be able to influence the binding of the endogenous agonist through 
protein-protein interactions between the two protomers.129 Others hypothesize the 
allosteric pocket is likely proximal to or within the transmembrane domains.128 More 
research is needed to characterize the allosteric binding site for GLP-1R before such 
hypotheses can be confirmed. Nevertheless, allosteric ligands offer the prospect of 
greater receptor selectivity due to higher sequence divergence in allosteric sites across 
receptor subtypes relative to the conserved orthosteric domain.124  
 Finally, to demonstrate that the truncated GLP-1 analogues are suitable for 
imaging, an in vitro cell study was done with the 68Ga labelled peptide 37c with 
CHO/GLP-1R cells as well as wild type CHO cells that do not express GLP-1 receptor. 
The study was done in triplicate and approximately 1 million cells were added to each 
test tube, excluding the background activity tubes which received no cells. Both glass 
and plastic test tubes were attempted, but it was discovered that glass retained much 
more background radioactivity than plastic, so the subsequent studies were done in 
plastic test tubes. In the first several attempts, the blocking experiment was done in 
advance, incubating the cells with 40 μg of exendin-4 and compound 26, respectively for 
1 hour at 37°C. Once the probe was prepared with good specific activity, it was 
incubated with the cells for 1 hour at 37°C. After washing with buffer several times, the 
tubes were counted on a gamma counter. However, this method resulted in no 
significant blocking. It was also observed that the overall process was too long and too 
many half-lives of 68Ga were passing. A different approach was used in which the 
blocking agent (40 μg) is added at the same time as the probe. Also, the time after 
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incubation was reduced with less washing steps. The results demonstrate that by adding 
the blocking agent and probe simultaneously to compete for the binding site, it was 
much more effective than pre-blocking (Figure 3.6).  
 
Figure 3.6 In vitro experiment for 37c   
 
It is evident that there is an interaction with the probe and GLP-1R transfected cells. As 
was previously discovered, blocking with exendin-4 did not seem to affect the binding 
since the probe is believed to be an allosteric agonist, binding to a separate site than the 
orthosteric site. The dose significantly decreased from blocking with 26 which is also 
expected since 26 should compete with the probe, 37c, for the same binding site. To 
confirm that the interaction with GLP-1R cells is specific a final cell study was performed. 
A concentration-dependent blocking study was executed in which radioactive 37c was 
added to both GLP-1R and CHO cells with increasing concentrations of 26 to block the 
receptor-specific interaction (Figure 3.7). If there was a specific interaction, there would 
be a concentration dependent decrease in activity as the concentration of the unlabelled 
blocking agent increases and replaces the radioactive probe.  
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Figure 3.7 Concentration-dependent blocking study for 37c with GLP-1R and CHO cells   
 
It was observed that there is a gradual decrease in activity in the GLP-1R cells, but not 
in the CHO cells in which the activity remained constant. It can be concluded that the 
probe is interacting specifically with the GLP-1R cells and are most likely acting at an 
allosteric site. Therefore, 37c (or 38c) is a promising potential PET agent for imaging 
beta cell mass in the pancreas which may offer improved selectivity for the GLP-1R and 
increased in vivo stability from the several unnatural amino acids it contains. 
 
3.4 Conclusions 
 The objective of this project was to synthesize and characterize a truncated GLP-
1 analogue and develop it into an imaging agent to target the GLP-1 receptor. This 
would allow for the non-invasive PET imaging of pancreatic beta cells and monitoring the 
onset and progression of type 2 diabetes. Before the peptides could be synthesized, the 
unnatural amino acids BIP 1 and BIP 2 needed to be synthesized since they are not 
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commercially available. The synthesis followed a reference procedure with some 
modifications. After the synthesis and characterization of the small molecules, three 
peptides were synthesized containing the two BIPs: one with a lysine on the C-terminus, 
one with a lysine and AEEA linker and the last with no additions (26). The two peptides 
containing the lysine were developed into imaging agents 37a and 38a incorporating a 
DOTA chelator onto the lysine side chain. Labelling studies were performed, 
incorporating both cold 69/71Ga and radioactive 68Ga into the two peptides. In both cases, 
the peptides were labelled with 68Ga in good radiochemical yields, with high specific 
activities and excellent radiopurities. To determine their ability to target GLP-1R and act 
as potential imaging agents, several in vitro binding assays were performed. The first 
assay determines the affinity of the peptide for GLP-1R and its ability to competitively 
displace [125I]exendin-4(9-39) as a measure of its IC50 value. This assay showed that 
neither peptide was able to displace exendin-4(9-39). However, it was discovered that 
the peptides were still able to act as GLP-1R agonists and stimulate cAMP production. 
This result prompted us to hypothesize that the peptides may be acting as allosteric 
agonists and binding to a site distinct from the site that exendin-4 or GLP-1 targets. Even 
if the peptides are targeting a different site, they remain potential imaging agents as they 
do bind to GLP-1R. To determine if the peptides have the potential to image in vivo, an 
in vitro cell study was performed. The results show that the probe is blocked with the 
control compound 26 and not with exendin-4. Furthermore, the cell blocking study 
demonstrates that the probe is binding specifically to the GLP-1R as it showed a 
concentration dependent decrease in activity with increasing concentrations of 26. In 
contrast, no significant change in activity was found in CHO cells as the concentration of 
26 was increased. This confirms that 37c and/or 38c has potential to be a PET probe for 
monitoring beta cell mass in the pancreas that may offer greater receptor selectivity in 
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binding through an allosteric site. In addition, it was previously discovered that the 
charge distribution of the peptide backbone is important for probe clearance. Compared 
with GLP-1, the synthesized peptides have a significant decrease in the amount of 
positive charges which may lead to reduced retention in the kidneys and ultimately better 
visualization of the probe in the pancreas. However, it is important to note that recent 
studies have concluded that it is impossible to visualize rodent pancreatic islets in vivo 
and must look at either ex vivo organ distribution or larger animal models such as 
nonhuman primates.130  
 
3.5 Experimental Procedures 
3.5.1 General Experimental procedure for peptides 
All Fmoc protected amino acids and coupling agents, except Fmoc-Lys(Mtt)-OH (Nova 
Biochem),  HATU (Nova Biochem), and HCTU were obtained from Peptides 
International. Fmoc-Rink amide MBHA resin (4-(2’,4’-dimethoxyphenyl-(9-
fluorenylmethoxycarbonyl)-aminomethyl)-phenoxy-acetamidonorleucyl-4-methyl 
benzhydrylamine resin) was obtained from Nova Biochem. RP-C18 Sep-Pak© cartridges 
were obtained from Waters. 68Ge-68Ga generator was obtained from Eckert and Ziegler. 
3.5.2 Peptide Syntheses 
Fmoc-based solid-phase peptide synthesis was carried out manually with 0.05 or 0.1 
mmol of 0.52 mmol/g Fmoc-Rink amide MBHA resin and a 3-fold excess of the protected 
amino acids. Fmoc removal, carried out with 20% piperidine in N,N-dimethylformamide 
(DMF) over two cycles (5 and 15 min), was followed by amino acid activation with 3 eq 
O-(1H-6-Chlorobenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
(HCTU) and 6 eq N,N diisopropylethylamine (DIPEA) (5 min) and subsequent coupling 
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over 30 and 60 min cycles. Coupling of Fmoc-protected 2-[2-(2-
aminoethoxy)ethoxy]acetic acid (AEEA) followed the same methodology used in amino 
acid coupling. Full deprotection of synthesized peptides was accomplished using a 
solution of 95% TFA (v/v), 2.5% H2O (v/v), 2.5% triisopropylsilane (v/v) over 5 hours. 
The cleaved peptides were then precipitated using tert-butyl methyl ether (TBME) and 
centrifuged at 2200 rpm for 15 min. After decanting, the peptide pellet was rinsed with 
TBME, vortexed and centrifuged again. Following the removal of the supernatant, the 
peptide pellets were dissolved in water, frozen at 78°C and lyophilized overnight. In 
order to monitor reaction progress and peptide purity via HPLC, small samples of the 
resin were cleaved using the same procedure as outlined above for full deprotection. 
3.5.3 Purification by RP-HPLC / ESI-MS 
Peptides were analyzed using a reverse-phase analytical HPLC column (SunfireTM RP-
C18 column 4.6 x 150 mm, 5 μm). This system was equipped with a Waters 600 136 
controller, Waters Prep degasser, and Waters MassLynx software (version 4.1). 
Employed mobile phases were 0.1% TFA in acetonitrile (eluent A) and 0.1% TFA in 
water (eluent B). The linear gradient used was 30-40% of A with a flow rate of 1.5 mL 
min-1 over 10 min. The column eluate was monitored using a Waters 2998 Photodiode 
array detector set at 220 and 254 nm. Peptides were purified using a reverse-phase 
preparative HPLC column (SunfireTM Prep RP-C18 OBDTM column 19 x 150 mm, 5 μm) 
on the same system mentioned above. The detection method along with eluents and 
gradients were the same as those stated above, with the exception of the flow rate being 
set at 20 mL min-1. The collected fraction was then lyophilized to a solid and 
subsequently analyzed by ESI-MS (electrospray ionization mass spectrometry) (Waters 
Micromass Quattro MicroTM API). Purity of final products was determined by analytical 
RP-HPLC. 
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3.5.4  69/71Ga Labeling 
In a typical reaction, 5 mg of the DOTA-peptide was dissolved in 0.1 M pH 4 NaOAc 
/HOAc buffer. Chelation was carried out using a three-fold excess of anhydrous GaCl3 at 
75°C over 30 minutes. The resulting mixture was cooled prior to purification by a plus 
C18 RP Sep-Pak© (conditioned with 6 mL of ethanol and 25 mL of water). After passing 
the reaction mixture through the Sep-Pak©, 10 mL of water was used as eluent in order 
to wash out residual unreacted GaCl3. A 6 mL aliquot of EtOH was used to wash out the 
labelled product. The resulting solution was then dried on a rotary evaporator, mixed 
with 5 mL of H2O, frozen at -78°C and subsequently lyophilized overnight. 
3.5.5  68Ga Radiolabeling 
To a clean glass microwave vessel was added 200 μL of a DOTA-peptide solution (0.1 
mg/mL in pH 3.5 HEPES buffer). This aliquot was dissolved in 800 μL of the buffer to 
which ~300 MBq 68Ga was added, freshly eluted from the Ge-68/Ga-68 generator using 
3 mL of 0.1 M HCl. Purification and isolation of 68Ga was achieved using a Phenomenix 
Strata-X-C polymeric strong cation exchange column (30 mg/mL) with 0.05 N HCl in 
acetone as the eluent. The reaction mixture was then manually heated in an oil bath at 
90°C for 10 minutes, prior to Sep-Pak© purification using a light RP-C18 SPE Sep-Pak 
cartridge© (conditioned with 5 mL of ethanol and 5 mL of water). After passing the 
reaction mixture through the Sep-Pak©, 3 mL of water was used as eluent in order to 
wash out residual unreacted 68Ga materials. A 3 mL aliquot of EtOH was used to wash 
out the radiolabeled product. After evaporation of the solvent using N2 (g) in an oil bath, 
the reaction progress and product purity was analyzed using analytical RP-HPLC 
(SunfireTM RP-C18 column 4.6 x 150 mm, 5 μm) coupled to a gamma detector, prior to 
further use in cell studies. HPLC system employed a Waters 1525 Binary HPLC pump, 
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Waters 2487 dual absorbance detector, Waters In-Line degasser and Breeze software 
(version 3.30). 
3.5.6 Binding Assays 
All GLP-1 receptor binding studies were conducted using Chinese hamster ovary cells 
stably transfected with the human GLP-1 receptor (CHO/GLP-1R). Receptor binding was 
measured by the displacement of [125I]-exendin-9-39 with increasing concentrations of 
the synthesized 69/71Ga-labeled GLP-1 analogues, using a previously published method. 
Briefly, CHO/GLP-1R cells were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM, Invitrogen) containing 10% fetal bovine serum (Invitrogen). On the day of the 
experiment, cells were rinsed 2X with Hank’s buffered saline solution (HBSS) and 
dissociated in HBSS containing 2 mM EDTA. Approximately one million cells were 
incubated for 60 min at 37°C in binding buffer (DMEM containing 0.1% Trasylol (Bayer) 
and 0.1% bovine serum albumin (Sigma), pH 7.4), 0.77 μmol [125I]exendin-4(9-39) 
(Amersham) and variable concentrations of each GLP-1 analogue (10-6 to 10-12 M). After 
incubation, cells were centrifuged at 2800 rpm for 15 min. After removal of the 
supernatants, the cell pellets were washed with 200 μL of cold binding buffer and re-
centrifuged before the final pellet was counted in a gamma counter.  
 
3.5.7 cAMP Studies 
Activation of the GLP-1 receptor by the peptide analogues was assessed by stimulation 
of cAMP. Briefly, CHO/GLP1R cells were plated at a density of 1x105 cells/well in a 24-
well plate 48 hours prior to the day of the experiment. Cells were incubated for 30 min at 
37°C in DMEM containing 1 μM 3- isobutyl-1-methylxanthine (IBMX; Sigma) and 
increasing concentrations of the peptide analogues (10-6 to 10-12 M). Media was 
removed, cells were rinsed twice with cold HBSS and scraped in 200 μL of 80% ethanol. 
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cAMP levels were measured using a cAMP radioimmunoassay kit (Perkin Elmer, 
Shelton CT) as per the manufacturer’s instructions.  
 
3.5.8 In Vitro Imaging 
CHO/GLP-1R cells were added to equal approximately one million cells per plastic tube. 
Three test tubes containing cells did not receive any radiolabelled peptide; three tubes 
did not contain any cells and were incubated with 1-2 MBq 68Ga labelled probe; three 
tubes with cells were incubated with 1-2 MBq 68Ga labelled probe; three tubes were 
incubated with 1-2 MBq 68Ga labelled probe and 40 μg exendin-4; and three tubes were 
incubated with 1-2 MBq 68Ga labelled probe and 40 μg compound 26. The volume of all 
the test tubes was equal to 500 µL and the tubes were incubated for 1 hour at 37°C. 
After the incubation period, the tubes were centrifuged and the media decanted off. Cells 
were rinsed with binding buffer (DMEM + 0.1% BSA [bovine serum albumin]) and 
centrifuged (4x). The media was decanted off and was counted on a gamma counter. 
The same procedure was repeated for the concentration-dependent blocking study for 
both the CHO and GLP-1R cells. Each cell line was blocked with varying concentrations 
of 26 (10-4 to 10-9 M).  
 
3.5.9 General Experimental Procedure for small molecules 
Solvents and reagents were used without further purification, and purchased either from 
VWR, Fisher Scientific, or Sigma-Aldrich. Sterile, deionized water was used in all 
aqueous procedures. Analytical TLC was carried out on EMD silica gel 60 F254 plates, 
and column chromatography was performed using Merck silica gel 60 (230-400 mesh). 
1H and 13C NMR data were obtained using a Varian 400 spectrometer. Chemical shifts 
are reported in parts per million (δ) from tetramethylsilane (0 ppm) and are referenced to 
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the residual proton in the deuterated solvent: CDCl3 (7.26 ppm) and DMSO-d6 (2.48 
ppm) for 1H NMR.  Multiplicities are described as s (singlet), d (doublet), t (triplet), q 
(quartet), m (multiplet) and br s (broad singlet). Coupling constants (J) are reported in 
Hertz (Hz).  High resolution mass spectra (HRMS) were obtained using electron 
ionization (EI).  
Synthesis of BIP 1117 
Synthesis of boc-L-tyrosine o-triflate methyl ester, 27 
To a solution of Boc-L-tyrosine methyl ester (10.16 mmol, 3.00 g) and pyridine (25.94 
mmol, 2.09 mL) in CH2Cl2 (8 mL), at – 78°C under N2 was slowly added triflic anhydride 
(12.19 mmol, 2.05 mL). The solution was stirred for 2 hours. After this time, it was 
removed from the dry ice, and water was added (12 mL) and the layers were separated. 
The organic layer was washed with 0.5 M NaOH (2×12 mL) and 15% aqueous citric acid 
(2×12 mL). The organic layer was dried over MgSO4, filtered and concentrated to give 
the crude product as a red solid (2.13 g) that required no further purification.                  
Yield: 71%. 1H NMR (400MHz , CDCl3) = 7.17-7.24 (m, 4H), 4.99-5.01 (br m, 1H), 4.55-
4.58 (br m, 1H), 3.69 (s, 3H), 3.13-3.16 (m, 1H), 3.00-3.03 (m, 1H), 1.38 (s, 9H) 
Synthesis of (S)-methyl 2-(tert-butoxycarbonylamino)-3-(2’-methylbiphenyl-4-yl) 
propanoate, 28 
Potassium carbonate (3.28 mmol, 399 mg), o-tolylboronic acid (3.51 mmol, 477 mg) and 
tetrakis(triphenylphosphine) palladium (0.07 mmol, 85 mg) were added to dry toluene 
(10 mL). The mixture was degassed and flushed with N2 and heated to 80°C. At this 
point, 27 (2.34 mmol, 1.00 g) was dissolved in toluene (1.3 mL) and was maintained at 
80°C overnight. The following morning, the reaction was cooled and filtered through 
celite. The filtrate was washed with 0.5 M NaOH (2×5 mL) and 15% citric acid (2×5 mL). 
 81 
 
The organic layer was dried over MgSO4, filtered and concentrated. The crude mixture 
was purified by silica gel column chromatography, eluting with 15% EtOAc in hexanes. 
The relevant fractions were combined and the solvent reduced by rotary evaporation to 
yield the pure product as a yellow oil. Yield: 75%. 1H NMR (400 MHz , CDCl3): δ 7.17-
7.26 (m, 4H), 4.63-4.67 (br m, 1H), 3.75 (s, 3H), 3.16-3.19 (m, 1H), 3.08-3.11 (m, 1H), 
2.27 (s, 3H), 1.42 (s, 9H) 
Synthesis of (S)-2-(tert-butoxycarbonylamino)-3-(2’-methylbiphenyl-4-yl)propanoic 
acid, 29 
The pure product 28 (1.99 mmol, 733 mg) was dissolved in a 1:1 THF:H2O (6 mL). While 
stirring at room temperature, 1 M NaOH (4.98 mmol) was added and reacted for 3 hours. 
After this time, THF was removed during rotary evaporation and EtOAc was added. It 
was washed twice with 1 M NaHSO4 (2×4 mL). The organic layer was dried over MgSO4, 
filtered and concentrated to yield the title compound as a pale yellow solid. Yield: 86%. 
1H NMR (400 MHz , DMSO-d6): δ 7.14-7.32 (m, 4H), 4.15-4.18 (br m, 1H), 3.06-3.08 (m, 
1H), 2.85-2.89 (m, 1H), 2.21 (s, 3H), 1.32 (s, 9H) 
Synthesis of (S)-1-carboxy-2-(2’-methylbiphenyl-4-yl)ethanaminium 
trifluoroacetate, 30 
Compound 29 (1.90 mmol, 676 mg) was dissolved in 1:1 DCM:TFA (10 mL) and stirred 
overnight to form the TFA salt. The next morning, the solution was azeotroped with DCM 
and CHCl3 and was concentrated under rotary evaporation to yield the salt as a brown 
solid.         Yield: 90%. 1H NMR (400 MHz , DMSO-d6): δ 7.18-7.32 (m, 4H), 4.15-4.35 
(br m, 1H),  3.17-3.19 (m, 1H), 3.12-3.16 (m, 1H), 2.24 (s, 3H) 
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Synthesis of (S)-2-((9H-fluoren-9-yloxy)carbonylamino)-3-(2’-methylbiphenyl-4-
yl)propanoic acid, 23 
The TFA salt 30 (1.69 mmol, 627 mg) was dissolved in a 1:4 H2O:THF (8 mL). DIPEA 
(10.16 mmol, 1.77 mL) was then added to the solution and once the pH was basic, 
Fmoc-OSu (2.03 mmol, 685 mg) was added. The reaction stirred at room temperature 
for 24 hours at which point, THF was removed during rotary evaporation and EtOAc (5 
mL) was added. The pH was acidified to pH 2 using 2 M HCl and the layers were 
separated. The aqueous layer was extracted twice with EtOAc (2×5 mL) and then the 
organic layers were combined and washed with water (2 mL). The organic layer was 
dried over MgSO4, filtered and concentrated. The crude mixture was purified by silica gel 
column chromatography, eluting with 30% EtOAc in hexanes containing 2% acetic acid. 
The relevant fractions were combined and the solvent reduced by rotary evaporation to 
yield 23 as a pure off-white solid.                                                                                  
Yield: 65%. 1H NMR (400 MHz , DMSO-d6): δ 7.18-7.32 (m, 4H), 4.55-4.65 (br m, 1H),  
3.17-3.19 (m, 1H), 3.12-3.16 (m, 1H), 2.24 (s, 3H) 13C NMR (400 MHz, DMSO-d6): δ 
20.1, 36.2, 46.6, 55.4, 65.7, 120.1, 125.2, 125.3, 125.9, 127.0, 127.1, 127.6, 128.8, 
129.5, 130.3, 134.7, 136.6, 139.3, 140.7,141.1, 143.7, 143.8, 156.0, 173.4 
HRMS: m/z [M]+ calcd: 477.1942; found: 477.1940. 
 
Synthesis of (2-ethyl-4-methoxy)phenylboronic acid117 
Synthesis of 3-ethylanisole, 31 
3-Ethylphenol (8.82 mmol, 1.0 mL) and K2CO3 (42 mmol, 5.80 g) were added to dry 
acetone (10 mL) and methyl iodide (42 mmol, 2.6 mL) was added. The mixture was 
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refluxed overnight. The following morning, the mixture was filtered through a celite pad 
and was washed with acetone. The filtrate and washes were concentrated, dissolved in 
DCM, filtered and concentrated to yield 3-ethylanisole 31.                                            
Yield: 55%. 1H NMR (400 MHz, CDCl3): δ 7.20-7.25 (m, 1H); 6.74-6.84 (m, 3H); 3.83 (s, 
3H); 2.65 (q, 2H, J=7.2); 1.28 (t, 3H, J=7.7)  
Synthesis of 4-bromo-3-ethylanisole, 32 
Compound 31 (4.85 mmol, 660 mg) and N-bromosuccinimide (5.34 mmol, 950 mg) in 13 
mL acetonitrile stirred in the dark, at room temperature overnight. The mixture was 
concentrated, redissolved in hexanes and filtered. The product was concentrated to yield 
32 as a yellow liquid. Yield: 75%. 1H NMR (400 MHz, CDCl3): δ 7.35-7.45 (m, 1H); 6.80 
(d, 1H, J=2.9 Hz); 6.63 (dd, 1H, J=3.0, 8.7 Hz;); 3.80 (s, 3H); 2.74 (q, 2H, J=7.5); 1.23 (t, 
3H, J=7.6) 
Synthesis of (2-ethyl-4-methoxy)phenylboronic acid, 33 
A solution of 32 (3.63 mmol, 781 mg) in dry THF (7.5 mL) was cooled to -78°C under N2. 
2.5 M n-BuLi in THF (4.72 mmol, 1.89 mL) was added slowly. Stirring was continued for 
2 hours at which point, tri-n-butylborate (5.45 mmol, 1.47 mL) was added at the same 
temperature. The reaction mixture was allowed to warm to 0°C and was quenched with 
HCl (8 mL). The layers were separated and the aqueous layer was extracted with 
EtOAC. The combined organic layers were washed with brine, and the organic layer was 
dried over MgSO4, filtered and concentrated. The resulting residue was dried under 
vacuum for 48 hours and the solid was stirred in hexanes for 1 hour. The pure white 
solid was collected by vacuum filtration to yield 33.                                                    
Yield: 40%. 1H NMR (400 MHz, DMSO-d6): δ 7.80 (br s, 2H); 7.41 (d, 1H, J=9);  
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6.68 (d, 2H, 7.5); 3.70 (s, 3H); 2.75 (q, 2H, J=7.5); 1.14, 3H, J=7.5). 13C NMR (400 MHz, 
DMSO-d6): δ 16.9, 27.9, 54.8, 109.9, 113.8, 135.4, 136.8, 150.6, 160.1.  
Synthesis of BIP 2117 
Synthesis of (S)-methyl 2-(tert-butoxycarbonylamino)-3-(2’-ethyl-4’-
methoxybiphenyl-4-yl) propanoate, 34 
Compound 27 (3.51 mmol, 1.50 g) in dry toluene (11 mL) was purged in N2 for 10 min. 
Potassium carbonate (4.92 mmol, 680 mg) in water (3.76 mL) and 33 (4.92 mmol, 885 
mg) were added to the mixture. Next, tetrakis(triphenylphosphine)palladium (0.25 mmol, 
283 mg) was added along with THF (7.4 mL) and ethanol (3 mL). The mixture heated to 
100°C for 4 hours. The solvents were removed during rotary evaporation and the residue 
was dissolved in DCM (20 mL). The organic layer was washed with 10% NaOH (aq) 
(2×20 mL) and 15% citric acid (aq) (2×20 mL). The organic layer was dried over MgSO4, 
filtered and concentrated. The crude mixture was purified by silica gel column 
chromatography, eluting with 15% EtOAc in hexanes. The relevant fractions were 
combined and the solvent reduced by rotary evaporation to yield the pure product as a 
yellow oil. Yield: 74%. 1H NMR (400MHz , CDCl3) = δ 7.10-7.30 (m, 5H); 6.86 (d, 1H, 
J=2.4 Hz); 6.78 (dd, 1H, J=2.5, 8.4Hz); 4.95-5.05 (br m, 1H); 4.60-4.70 (br m, 1H); 3.85 
(s, 3H); 3.71 (s, 3H); 3.05-3.20 (br m, 2H); 2.56 (q, 2H, J=7.5 Hz); 1.43 (s, 9H); 1.11 (t, 
3H, J=7.5 Hz)  
Synthesis of (S)-2-(tert-butoxycarbonylamino)-3-(2’-ethyl-4’-methoxybiphenyl-4-
yl)propanoic acid, 35 
The pure product 34 (2.59 mmol, 1.07 g) was dissolved in a 1:1 THF:H2O (10 mL). While 
stirring at room temperature, 1 M NaOH (6.47 mmol) was added and reacted for 3 hours. 
After this time, THF was removed during rotary evaporation and EtOAc was added. It 
was washed twice with 1 M NaHSO4 (2×10 mL). The organic layer was dried over 
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MgSO4, filtered and concentrated to yield the title compound as a pale yellow solid. Yield: 
85%. 1H NMR (400MHz , DMSO-d6): δ 7.26-7.29 (m, 2H); 7.15-7.20 (m, 2H); 7.04 (d, 
1H, J=8.3 Hz); 6.75-6.87 (m, 3H); 4.10-4.18 (br m, 1H); 3.77 (s, 3H); 3.02-3.05 (m, 1H); 
2.70-2.85 (m, 1H); 2.50 (q, 2H, J= 7.5 Hz); 1.32 (s, 9H); 1.02 (t, 3H, J=7.5 Hz) 
Synthesis of (S)-1-carboxy-2-(2’-ethyl-4’-methoxybiphenyl-4-yl)ethanaminium 
trifluoroacetate, 36 
Compound 35 (2.19 mmol, 873 mg) was dissolved in 1:1 DCM:TFA (16 mL) and stirred 
overnight to form the TFA salt. The next morning, the solution was azeotroped with DCM 
and CHCl3 and was concentrated under rotary evaporation to yield the salt as a brown 
solid.    Yield: 90%. 1H NMR (400MHz , DMSO): δ 7.26-7.29 (m, 2H); 7.15-7.20 (m, 2H); 
7.04 (d, 1H, J=8.3 Hz); 6.75-6.87 (m, 3H); 4.10-4.18 (br m, 1H); 3.77 (s, 3H); 3.02-3.05 
(m, 1H); 2.70-2.85 (m, 1H); 2.50 (q, 2H, J= 7.5 Hz); 1.02 (t, 3H, J=7.5 Hz) 
Synthesis of (S)-2-((9H-fluoren-9-yloxy)carbonylamino)-3-(2’-ethyl-4’-
methoxybiphenyl-4-yl)propanoic acid, 24 
The TFA salt 36 (2.10 mmol, 871 mg) was dissolved in THF (20 mL) and a solution of 
NaHCO3 predissolved in water (30 mL) was then added to the solution. Once the pH 
was basic, Fmoc-OSu (2.52 mmol, 850 mg) was added. The reaction stirred at room 
temperature for 48 hours at which point, THF was removed during rotary evaporation 
and water (40 mL) was added. The aqueous layer was washed with Et2O and the layers 
were separated. The aqueous layer was acidified to pH 1 using 2 M HCl and was 
extracted with EtOAc. The organic layers were combined and washed with water and 
brine. The organic layer was dried over MgSO4, filtered and concentrated. The crude 
mixture was purified by silica gel column chromatography, eluting with 30% EtOAc in 
hexanes containing 2% acetic acid. The relevant fractions were combined and the 
solvent reduced by rotary evaporation to yield BIP 2 as a pure off-white solid.                      
 86 
 
Yield: 65%.  1H NMR (400 MHz, DMSO-d6): δ 7.88 (2H, d, J=8.0 Hz); 7.82 (d, 1H); 7.67 
(2H, t, J=7.0 Hz); 7.30 (4H, t, J=8.0 Hz); 7.15 (2H, d, J=7.9); 6.99 (1H, d, J=8.4); 6.84 
(1H, d, J=2.4); 6.75, (1H, d); 4.10-4.30 (4H, m); 3.76 (3H, s); 3.10-3.20 (1H, m); 2.88-
2.98 (1H, m); 2.43 (2H, q, J=7.6); 0.94 (3H, t, J=7.5). 13C NMR (400 MHz, DMSO-d6): δ 
14.0, 15.4, 21.1, 25.7, 36.2, 46.6, 55.0, 55.5, 65.7, 111.1, 114.0, 120.1, 125.3, 
127.0,127.6, 128.2, 128.9, 130.7, 133.4, 136.2, 139.2, 140.7,142.4, 143.7, 143.8, 156.0, 
158.6, 173.4 
HRMS: m/z [M]+ calc: 521.2202; obs: 521.2210. 
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Chapter 4: Conclusions 
 
Molecular imaging has been shown to play a significant role in modern medicine 
due to its application in diagnostics and therapeutics. In order for the non-invasive in vivo 
visualization of biological processes to be feasible, it requires the development of an 
appropriately designed imaging probe. The research in this dissertation focused on the 
development and characterization of imaging agents. Both projects use gallium-68, a 
PET radioisotope that is becoming increasingly prominent in medical imaging. It offers 
several advantages including its facile production from a generator, low cost and 
convenient half-life.   
 The first project involved the development of the previously discovered candidate 
peptides into imaging agents. To accomplish this, a linker was coupled onto the N-
terminus of the peptides and DOTA was synthesized on-resin as part of the solid-phase 
peptide synthesis. After optimizations of 68Ga labelling conditions were completed, two 
peptides 7c and 9c were used in separate in vivo studies in mice containing different 
RHAMM-expressing cell lines. It was observed that the peptides do not function well as 
in vivo imaging agents. One reason may be due to the number of natural amino acids 
present in the sequences that can be degraded by various enzymes which leads to poor 
stability. The second aspect of this project was to develop novel peptides with affinity to 
RHAMM as well as improved stability through the incorporation of unnatural amino 
acids. This work involved the synthesis of 99 peptides on the tip workstation. The 
parallel synthesis unit allowed the synthesis of many peptides in small screening 
amounts that would otherwise be impossible to manually synthesize. The screening 
utilized RHAMM-coated magnetic/fluorescent beads and selected hit peptides based on 
fluorescence. This methodology provides a versatile and accurate screening strategy 
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using bulk magnetic and fluorescence separation. The screening strategy proved to be 
superior to the more common cell-based method which was inconsistent. Although the 
screen was consistent for positive and negative results and gave rise to positive hits, the 
error bars on the controls were large. The methods for washing the beads will need to be 
optimized in the future to obtain more precise results.  
The “beads on a bead” strategy requires the protein of interest to adsorb onto the 
magnetic/fluorescent beads in order to detect positive hit peptides. Typically, purified 
recombinant RHAMM is used in assays in which the protein is required, however, its 
synthesis is a very lengthy procedure that often results in low yields. It was realized that 
the shortened 7 kDa RHAMM was able to be synthesized as part of solid-phase peptide 
synthesis. This truncated version of RHAMM has not been previously used for studies, 
thus its ability to target HA was confirmed by an ELISA assay. This discovery may 
revolutionize RHAMM studies because the standard technique using recombinant 
RHAMM is very time consuming and RHAMM is difficult to purify. This method was very 
quick and can be easily modified without interruption of the binding sites. Thus the 
protein was completely biotinylated, but did not interfere with the lysines, which is the 
standard location for biotin. A second confirmation that 7 kDa RHAMM is potent is 
because the initial screen using this protein resulted in three novel analogues of peptide 
3 and six new analogues of peptide 1 with potential improved affinities for RHAMM. One 
of the replacements with improved affinity was confirmed in the alanine scan, offering 
validation to the screening method. Many of the improvements that were seen in both 
peptides were through the replacement of acidic residues with amino acids of similar 
acidity as well as more acidic, hydrophilic residues, such as cysteic acid. Other 
improvements included D-amino acid and hydrophobic amino acid replacements. These 
improvements may have allowed for a change in the conformation of the peptide to allow 
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for stronger binding to the RHAMM receptor. In addition, a total of 10 peptides were 
discovered with comparable affinities for RHAMM, but containing unnatural amino acids. 
This offers the possibility of increased stability in vivo while maintaining the same affinity 
for RHAMM. The positive hits will need to be synthesized and validated with further 
studies to confirm their affinity. Afterwards, the validated sequences with improved 
affinity for RHAMM may be further optimized through the combination of multiple amino 
acid replacements.  
The goal of the second project was to develop a previously discovered peptide, 
26, into an imaging agent. In this project, a lysine was added onto the C-terminus and 
modifications (DOTA) were performed on the side chain of the lysine. It was unknown 
whether a linker would aid or hinder the peptide’s affinity for GLP-1R, so both versions 
were synthesized as well as their cold 69/71Ga analogues. The results of the binding 
assays demonstrate the peptides are not effective agonists at the orthosteric site, but 
instead are allosteric agonists binding to a distinct site. They were unable to compete 
with a potent antagonist of the GLP-1R, exendin-4(9-39) and essentially had no IC50 
value. However, both peptides seemed to be acting as agonists and managed to 
stimulate cAMP production to obtain good EC50 values. The presence or absence of a 
linker did not affect the binding affinity so it was not used for further studies due to a 
shorter synthesis time. The in vitro experiment with the 68Ga labelled peptide 37c 
confirmed the results of the IC50 through the blocking study as there were no blocking 
effects seen when attempting to block the binding of the probe to GLP-1R with exendin-
4. However, full blocking was observed when self-blocking with 26 was attempted. 
Although the probe is clearly not binding to the same site as GLP-1 or exendin-4 on the 
GLP-1 receptor, it is binding somewhere on the receptor in order to produce cAMP. 
Finally, it was confirmed that the probe was interacting with GLP-1R in a specific manner 
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through a concentration-dependent blocking study with both GLP-1R and CHO cells. As 
the concentration of the blocking agent, 26, increased, the activity in the GLP-1R cells 
gradually decreased demonstrating competitive displacement of the probe. In contrast, 
the CHO cells exhibited consistently low activity independent of the concentration of 26. 
Therefore, the peptide(s) 37c and 38c remain promising imaging agents that may target 
the GLP-1R and provide a non-invasive and direct visualization of pancreatic islets in 
vivo. Future investigations will include the exploration of the functional cooperativity of 
the allosteric peptide with other GLP-1R agonists as well as an in vivo mouse study to 
determine the potential of the probe as an imaging agent.    
In conclusion, molecular imaging agents using the radionuclide 68Ga were 
developed for both projects. The previously discovered peptides in chapter 2 were found 
not to be adequate imaging agents in vivo and analogues were discovered using a 
“beads on a bead” screening approach. The analogues that were designed and 
synthesized have more promise as imaging agents for RHAMM due to the presence of 
unnatural amino acids that may increase their in vivo stability. In addition, the synthesis 
of 7 kDa RHAMM by solid-phase peptide synthesis allows for quick and easy production 
of the protein. The shortened version of the protein has the potential to revolutionize the 
methods used to explore RHAMM:ligand interactions. It allows for the characterization of 
the binding profile of RHAMM interacting with a ligand through NMR or mass 
spectrometry. In addition, it permits access to a variety of screening methods to discover 
new ligands for RHAMM, such as the “beads on a bead” strategy used in this 
dissertation. Chapter 3 highlights the synthesis and development of an allosteric agonist 
for GLP-1 into an imaging agent. Due to the binding at a distinct site it has the potential 
for greater receptor selectivity and offers a promising PET imaging probe for the 
visualization of beta cell mass in the pancreas. Furthermore, most current GLP-1R 
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imaging agents are highly charged and large peptides which results in their high kidney 
uptake and retention. The imaging probe that was synthesized and discussed offers a 
new class of GLP-1R imaging agents that are much lower in molecular weight and less 
charged. These characteristics may allow for decreased kidney uptake and hence the 
visualization of the pancreas in vivo. The small allosteric peptide represents a unique 
and novel agent for studying type 2 diabetes as well as a tool for further understanding 
of the allosteric binding site of GLP-1R. 
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